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Abstract 
Conformation-dependent antibodies serve as important tools for understanding the 
mechanism of aggregation on the pathway of amyloid fibril formation. Furthermore these 
antibodies may be used for diagnostic and therapeutic purposes because of their fibril­
reactive nature. One of the important drawbacks of these antibodies is their potential for 
cross-reactivity with the soluble precursor proteins in addition to the amyloid fibrils. 
11-1F4 is a murine monoclonal antibody generated against the amyloid fibrils of 
the immunoglobulin light chain Len. This antibody has been shown to recognize amyloid 
fibrils composed of other light chains regardless of their subgroup (A or 1e). In addition, 
this reagent binds amyloid fibrils composed of non-light chain precursor proteins. The 
11-1F4 antibody is also selectively reactive with the fibrillar form of the precursors and 
does not recognize the soluble protein. It therefore binds a common conformational 
epitope within amyloid fibrils. More specifically, the epitope recognized by 11-1F4 on 
the Len peptide was recently localized to the first 22 N-terminal amino acids. 
In the studies presented here, Eu +3 -linked Immunoabsorbant Assays (EuLISA), in 
vitro fibril formation assays, and limited proteolysis experiments have been used to 
provide further insights into the conformation of the Len 1-22 peptide and its role in light 
chain fibrillogenesis. In vitro fibril formation assays demonstrated the fibrillogenic nature 
of this region. Single amino acid substitutions of Len 1-22, designated P8A and P8S, 
were also used in these studies and the results were compared with the native Len 1-22 
molecule. The proline residue at the 8th position, previously hypothesized to be critical in 
the conformation of Len 1-22, was shown to affect the binding of the 11-1F4 antibody 
and the kinetics of fibril formation of the Len 1-22 peptide. In addition, different 
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fragmentation patterns were obtained when Len 1-22 and P8A Len 1-22, both in the 
soluble and fibrillar forms, were subjected to limited proteolysis experiments. This 
further supports the idea that a single site mutation at this position determines the 
conformation of this peptide, which in turn alters its serological reactivity and 
amyloidogenic propensity. 
Understanding the conformation of the epitope on amyloid fibrils recognized by 
this antibody may be important in designing drugs in future which may diminish amyloid 
fibril formation or disaggregate already formed fibrils. 
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Chapter 1. Introduction 
Background and Significance 
Amyloidosis is the name given to a group of diseases where normally soluble 
proteins ( either natively folded or unfolded) aggregate and deposit as insoluble fibrils, 
resulting in functional or structural damage in the organs they effect. There are over 24 
proteins that differ in size, amino acid sequence, function and structure that are known to 
form fibrils [1]. Alzheimer's disease (AD), transmissible spongiform encephalopathies 
{TSE), dialysis-associated amyloidosis (DRA) and immunoglobulin light chain {AL) 
amyloidosis are the most commonly known types of these diseases [2]. In spite of the 
differences in their soluble precursor proteins, the fibrils all share common structural and 
tinctorial properties [3]. For example, when viewed microscopically they are able to bind 
the dye Congo Red resulting in red-green birefringence under polarized light. They also 
bind Thioflavin T (ThT) resulting in an increase in fluorescence intensity and 30-nm-red 
shift in the excitation maximum [ 4]. Amyloid fibrils also have similar morphologies. 
They are of indeterminate length, unbranched, twisted and 7-10 nm in diameter and show 
a similar x-ray diffraction pattern indicative of their Cross-P-sheet structures [3][4]. 
Light chain amyloidosis (AL) is the most common form of systemic amyloidosis 
in Western countries, with an occurrence of 1 case per 100,000 person years in USA [5]. 
It results from the deposition of pathogenic immunoglobulin light chains as amyloid 
fibrils in various organs including kidney, liver, spleen and heart [1]. It often occurs in 
patients with a related plasma cell dyscrasia, multiple myeloma, where patients produce 
excessive amounts of immunoglobulin light chains [6]. 
1 
Immunoglobulins, also known as antibodies, are composed of two light and two 
heavy chains connected by a series of disulfide bridges and non-covalent interactions. 
The N-terminal regions of both heavy and light chains form the antigen binding site [7]. 
Immunoglobulin light chains {LC) were first identified by Dr. Henry Bence Jones as a 
urinary substance in patients with multiple myeloma [8]. There are two classes of human 
immunoglobulin light chains namely A and 1e, which are further divided into 6 subgroups 
of A (A 1, All, AIII, AIV, A VI, A VIII) and 4 subgroups of 1e ( 1e 1, rll, dll, rlV) light chains 
based on the amino acid variations and germline gene usage [9][10]. 
There are two structural parts to the immnunoglobulin light chain, the variable 
(VL) and constant domains (CL); located at the N- and C- terminals, respectively. The VL 
is heterogeneous in amino acid sequence, whereas constant domains of different 
immunoglobulin light chains have similar amino acid sequence [7]. The AL fibrils 
formed from immunoglobulin light chains are predominantly composed of the V L region 
and a small portion, (generally < 20 amino acids) of the CL region [ 5]. 
Only a small percentage of light chains form amyloid in vivo [ 11], perhaps due to 
the fact that there are many different factors involved in AL: 1) increase in protein 
concentration of light chains secondary to their production by an aberrant monoclonal 
plasma cell clone; 2) destabilizing variations in the amino acid sequence of the V L 
domain due to somatic mutations; 3) proteolytic digestion of the LCs (generating the V L); 
4) change in the physiological environment (pH, ions, solutes) of certain tissues; and 5) 
destabilizing mutations that weaken the dimer interface of V L and resulting in monomeric 
VL formation [5] [12] [13]. The majority of these factors result in a destabilization of the 
LC structure mainly in the V L region which is thought to be the main driving force for 
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formation of LC amyloid fibrils [12] [13] [14] [15]. A schematic representation of LC 
fibril formation is shown in Figure 1.1. 
The importance of destabilizing the native conformation of amyloidogenic 
precursor proteins such as P2-microglobulin (P2m ), Transthyretin (TTR), or light chains 
and the subsequent formation of partially folded intermediates on the pathway to fibril 
formation is well described [16] [17] [18]. The general mechanism for fibril formation is 
described in the literature as a seed-dependent polymerization reaction that, in it's 
simplest form, includes three steps; 1) destabilization of the amyloidogenic protein 
generating a partially unfolded conformation ( or in the case of natively unfolded proteins, 
partial folding of the protein); 2) The self association of these partially folded structures 
generating the 'seed' or 'nucleus', this step is defined kinetically by a 'lag phase'; and 
... ll(i-------- Fibril formation -----------1>� 
--•�- Nucleation phase---->..__....,__ Extension phase___,. 
I -<--)i Nucleus -<---
Figure 1.1. Proposed Mechanism for the Seed Dependent Fibril Formation and 
Propagation from Globular Precursor Proteins 
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3) Addition of similar protein structures to the seed and the extension of fibrils [ 19]. The 
native secondary structure of many amyloidogenic proteins eg. light chains, P2m, or TTR 
are composed of P-sheets. In these cases, destabilization of their native structure is 
thought to involve the edge strands of the P-sheets that dissociate from rest of the 
structure, allowing the proteins to self associate by intermolecular H-bonding, resulting in 
edge-to-edge aggregation and amyloid fibril formation [18] [20]. 
In addition to fibrils, light chain proteins form other pathologic aggregates such as 
amorphous aggregates in the glomerular basement membrane ( associated with light chain 
deposition disease (LCDD)) and casts in the renal tubules (in myeloma cast nephropathy) 
[13] [21]. In many cases the production of LC proteins by aberrant plasma cells does not 
result in any type of aggregation. The factors listed above may help explain why only 10-
15% of the multiple myeloma patients suffer from AL amyloidosis [6] [18]. 
Structural Factors Affecting Fibrillogenesis 
The major reasons for the destabilization of the V L domain in the LCs, is the 
amino acid variation that is a result of somatic mutations in the V L sequence during the 
immune response [11] [14]. The somatic mutations, according to where they are located 
in the sequence of the V L domain, may have a severely destabilizing effect on the 
structure that can result in aggregation and pathological behavior of LC protein [10] [12]. 
Unfortunately because of the inherent heterogeneity of amino acid sequences in the V L 
domain, there is no single amino acid substitution in the V 1 domain which can be shown 
to be causative [7] [ 14]. 
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Of the two light chain isotypes, the A light chains are predominant in amyloid 
deposits (A / 1e ratio, 3: 1) [ 1] [ 11]. Furthermore, the light chains belonging to A VI 
subgroup, when expressed as free LC proteins, are almost invariably associated with 
amyloidosis [22]. However immunoglobulin light chains belonging to the gene families 
Vrl and VrlV are also highly associated with AL amyloidosis. Most of the VdV light 
chains overproduced in plasma cell diseases were reported to form amyloid deposits in 
patients [23]. In addition, pathological 1e light chains were also shown to be responsible 
for other deposits such as LCDD [24]. Therefore, studying the structural characteristics of 
VrlV light chains will likely be important for understanding the basis for different types 
of deposition diseases [10]. 
A group of three immunoglobulin light chains belonging to rlV subgroup have 
been intensively studied in vitro. Two of these proteins, Sma and Rec were identified in 
patients with AL and are considered to exhibit pathological behavior and can form fibrils 
in vivo and in vitro [13]. The light chain Sma was isolated from the lymph node-derived 
amyloid fibrils of a patient suffering from AL amyloidosis. The light chain Rec was 
isolated from the urine of a patient with AL amyloidosis. In addition, a third light chain, 
Len was isolated from the urine of a patient excreting 50g/day of light chain protein and 
suffering from multiple myeloma, but did not have amyloidosis (i.e. a non-aggregating 
(in vivo) rlV LC) By convention, light chain proteins were named using a 3-letter 
identifier associated with the patients surname - to maintain greater anonymity however, 
this convention has recently ceased [ 13]. 
This group of three proteins provide a means to characterize the structural basis 
for the pathological character of Rec and Sma and the nonpathological character of Len. 
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Therefore, the V L domains of these three light chains were synthesized as recombinant 
proteins in E.coli and the crystal structures of the patient-derived and synthesized 
proteins determined [ 13]. The structures of patient-derived and synthesized proteins were 
shown to be identical by this and other techniques. The sequences of the V L domains of 
three light chains were also compared (Figure 1.2). The pathological VLs (Rec and Sma) 
differ in sequence from the nonpathological light chain Len by 14 and 8 amino acids, 
respectively. The amino acid diversity observed between Len and Rec, and Len and Sma 
were different and located in different regions [13]. 
A comparison of the Len and Rec sequences showed that 8 of the 14 substitutions 
were in the Complementary Determining Region 1 (CDRl). These included three charge 
changes: neutral (serine) to negative (aspartate) at position 27d and 29 and positive 
(lysine) to neutral (threonine) at position 30. There was only one residue difference 
within their CDR2 regions at position 53, that involved amino acids of similar nature, i.e., 
the threonine in Len was substituted for Ser. The differences within their CDR3 regions 
included the residues at position 96 (tyrosine to proline) and 97 (serine to threonine). 
There was only one exchange in the FRl at position 15 where a leucine in Len was 
substituted for proline in Rec. The remainder of the residue differences were located in 
FR4 at positions 100 (glutamine to glycine) and 104 (leucine to valine). 
Four of the 8 residues, which were different between Len and Sma, were located 
in the CDR3 region. Glutamine 89 and threonine 94 were substituted for histidine 
residues at both positions in the Sma. In spite of the differences between Len and Rec on 
the CDRl region, there were only two residue differences between Len and Sma in this 
region at position 29 and 30, but with a similar charge of the substituted amino acid. 
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Figure 1.2. Sequence Alignment of1e4 Subgroup Light Chain VL Domains 
P.W. Stevens et al., Protein Science (1995) Vol 4. 421-432 
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The other amino acid variations included residues at position 40 (proline in Len and 
leucine in Sma) and 106 (isoleucine to leucine). 
According to the previous sequence comparison between the pathological Rec and 
Sma and the non-pathological light chain Len, it is clear that a single amino acid 
substitution can not be associated with the amyloid fibril forming propensity of the 
pathological light chains in vivo. However some of the residues that are different in the 
V1 domain of these light chains are considered to be important for the protein stability, 
solubility, or exposure of the hydrophobic residues and dimer formation [13]. For 
example, the residue at position 40 (pro line in Len) is considered to be important in 
nonpathological behavior of Len. In the amyloidogenic light chain Sma, this position has 
a hydrophobic amino acid (leucine) which is solvent exposed in the tertiary structure. 
This property is thought to be a factor in Sma's amyloid assembly, because of the 
potential decrease in the protein solubility. In addition, the residue proline 96 in Rec, is 
thought be necessary for its increased dimerization which could also contribute to its self­
assembly and amyloid fibril formation. The presence of a proline residue at the 96th 
position is seen in some other Kand A light chains with amyloidogenic properties [13]. In 
spite of the sequence variations between Len and the pathological light chains, the x-ray 
structures of these three light chains were found to be identical (Figure 1.3). 
In another study, the sequence and x-ray structures of Len and a murine Kl light 
chain McPC603 were compared. The sequences of both light chains showed 81 % identity 
in their V1 domain and the x-ray structures showed that they were very similar in 
structure [10]. However, one residue in Len was considered to be important in its protein 
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Len Rec 
Figure 1.3. Comparison of the X-ray Structures of Len and Rec (RCSB Protein 
Data Bank) (X-ray Structure for Sma is not available in Protein Data Bank) 
stability. According to x-ray structure this residue, located at position 15  (leucine in Len), 
is thought to participate in a hydrophobic microdomain involving residues 78, 83 and 
1 06. Leucine in Len is substituted for Alanine in McPC603. Alanine being a smaller 
amino acid is thought to increase the solvent accessibility of this residue by decreasing 
this hydrophobic domain and thereby decreasing the stability of the entire domain [10]. In 
addition, when the sequences of Rec and Len V L domains were compared, Rec was 
shown to have a proline substituted at position 15, which is less hydrophobic than leucine 
and a main chain modifying residue [ 13] . 
When the thermodynamic stabilities of recombinant Sma, Rec and Len (rSma, 
rRec, and rLen) were determined by guanidine hydrochloride induced unfolding, in which 
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unfolding was monitored by intrinsic tryptophan fluorescence and circular dichroism, and 
compared, the Len V L domain exhibited a greater stability than the V L domains of both 
Sma and Rec [ 14] . This study also showed that the pathological V LS Sma and Rec formed 
fibrils in vitro within 100 hrs as monitored by ThT fluorescence emission, whereas Len 
did not form fibrils even after 400 hrs of incubation in the same assay. The fibrillogenic 
propensity of Sma and Rec therefore correlated with the lower stability of their V L 
domains as compared to Len. In order to provide insight into the role of each substitution 
in the V L domains, ie where the pathological light chains Rec and Sma are different from 
Len, individual or groups of amyloid associated mutations were generated in the Len 
sequence. The stabilities of the site directed mutants of Len and their fibril forming 
capacities were compared with the native Len V L domain. With few exceptions, the 
mutations which resulted in the thermodynamic destabilization of the Len V L domain also 
caused Len to form fibrils more readily. In contrast, the rare stabilizing mutations had the 
opposite effect resulting in non-fibrillogenic mutants [ 14] .  In addition, the rLen V L was 
found to form fibrils under destabilizing in vitro conditions, suggesting that it is the 
thermodynamic stability of the Len that contributed to its nonpathological behavior in 
vivo [14] . 
The role of thermodynamic stability in the generation of different types of 
aggregates including amorphous or amyloid fibrils has been extensively studied in 
literature [9] [ 12] [ 1 8] [25] . For example, increasing the thermodynamic stability of 
amyloidogenic proteins using stabilizers such as sucrose and trehalose decreased the 
fibrillogenicity of pathological light chains. In contrast, urea destabilized the structure of 
a non-pathological light chain and resulted in its fibril formation [ 1 5] .  These studies have 
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demonstrated that maintaining certain residues in the sequence of light chains is 
important for their structural characteristics, and predicting their pathological behavior 
[9] [ 1 8] as these residues determine the thermodynamic stability of the tertiary structure. 
Thirty-six amyloidogenic sequences ( 1 8  A and 1 8  K) were analyzed to search for pro­
amyloidogenic residues, i.e., substitutions at these positions occurred more frequently in 
amyloidogenic light chains. Substitution of some of these critical residues on a 
nonamyloidogenic Kl light chain Rei, background was shown to decrease the protein 
stability and increase its fibrillogenic potential in vitro [ 1 2] . In addition, a subsequent in 
vitro study showed that this light chain was capable of forming fibrils or amorphous 
aggregates according to how the structure was destabilized [ 1 8] .  In this study, Rei V L 
formed amorphous aggregates or amyloid fibrils depending on the position of the 
destabilizing amino acid substitution. For example, a mild destabilization of the VL by a 
single substitution of arginine to asparagine (R61 N) resulted in amyloid fibril formation, 
because this substitution only affected one of the salt bridges in the structure. The authors 
suggested that substitution of aspartate to isoleucine (D82I), involved in two types of salt 
bridges, resulted in the formation of amorphous aggregates, because this mutation caused 
substantially greater destabilization of the light chain. These results indicated that 
depending on the conformation of the partially folded intermediate during the unfolding 
process due to different substitutions on the protein sequence, was important in 
determining the type of the aggregate end product. Similar results were also obtained in a 
comparison of 2 A.6 VL proteins [9] .  One of these light chains (Jto) was isolated from a 
patient with multiple myeloma and tubular cast nephropathy with no signs of AL 
amyloidosis. The other light chain (Wil) was isolated from a patient with AL 
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amyloidosis. Although there were no significant structural differences between the two 
A.6 light chains manifested in the x-ray crystallographic structures, there were two 
residues in Jto ( aspartate 29 and arginine 68) which were found to form an ionic 
interaction that increased the protein stability. This structural feature which is unique to 
Jto amongst l6 LC proteins, increased the protein stability sufficiently to render it non ­
amyloidogenic [9]. 
Given that the V L domain of immunoglobulin light chains including Sma and Rec 
are responsible for forming amyloid fibrils in vivo, with a high sequence and structural 
homology to the V L domain Len, determining how the Len V L domain forms fibrils in 
vitro and the structure of these fibrils may give an understanding of how the pathological 
light chains form fibrils in vivo. 
Factors Affecting Fibrillogenesis of V L Domains in vitro 
It has therefore been established that decreasing the thermodynamic stability of 
the V L domain by substitution of critical amino acid residues, increases the propensity for 
fibril formation in vitro and amyloidogenesis in vivo. In addition to these intrinsic factors, 
numerous environmental (extrinsic) factors severely influence the in vitro fibrillogenesis 
of V L domains. 
The kinetics of fibril formation by the VL domain of Len were determined at 
different pH's (pH 2 and pH 7) in the presence of low amounts of urea and at 
physiological pH with vigorous stirring [26] [27]. The rate of fibril formation under all of 
these conditions was inversely proportional to protein concentrations and directly 
proportional with increased urea concentrations up to 4M [27]. The reason for these 
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effects was further studied by monitoring the conformational changes occurring on the 
pathway to fibril formation of Len, using a variety of biophysical methods such as near­
and far-UV CD, intrinsic and ANS fluorescence, acrylamide -tryptophan quenching, 
small angle x-ray scattering and thermal stability [28]. 
At pH 7, Len at high concentrations ( 40 µM) was mostly in a dimeric 
conformation with a higher stability, but at lower concentrations (0.79 µM) was 
predominantly monomeric with a lower thermodynamic stability, as demonstrated by 
their Cm values determined using urea denaturation unfolding experiments [27]. The far 
and near UV CD spectrum, intrinsic fluorescence, ANS fluorescence and acrylamide 
quenching showed that there was a slight rearrangement in Len conformation even at 4 M 
urea concentration. Small angle x-ray scattering data provided evidence that Len, at a 
high urea concentration, remained as a globular protein but its dimeric conformation 
dissociated into monomers with increasing urea concentrations (up to 4M), which favored 
fibrillogenesis. In relation to Len's fibril formation kinetics at pH 7, the rate of fibril 
formation was measured by using different concentrations (0. 79 µM to 327 µM) of Len in 
a range of urea concentration (0-4 M) and the conformational changes were monitored 
using various biophysical methods (as above). The results showed that at a given urea 
concentration, the rate of fibril formation decreased with increasing protein 
concentration, and at a given protein concentration the rate of fibril formation increased 
with increasing urea concentration. According to the results of the biophysical analyses, 
there were no conformational changes occurring at the early stages of fibril formation, 
but rather the conformational change occurred parallel to fibril formation. Given that Len 
remained globular even at 4M urea but the rate of the fibril formation increased, the 
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increased rate of fibril formation was considered to be more associated with the 
dissociation of the dimers to monomer, which indirectly affected the stability of Len, and 
thus its rate of fibril formation (Figure 1 .4) [27] . 
The conformation of Len on its pathway to fibril formation and the rate of fibril 
formation of Len at pH 2 were also studied by the same group [26]. The aim of these 
studies was to provide insight into the conformational changes of Len during the early 
stages of fibril formation. The structure, compactness and dimerization state of Len were 
very similar in both pH 2 and at near physiological pH (pH 8) as demonstrated by Far and 
Near UV Circular Dichroism, Attenuated Total Reflectance Fourier Transform Infrared 
Spectroscopy (ATR-FTIR), ANS (anilinonaphtalane-8 sulphonic acid) fluorescence and 
the intrinsic tryptophan fluorescence. The kinetics of fibril formation in vitro were 
studied at a lower pH because the kidneys are considered to have a destabilizing 
environment with a significantly lower pH than physiological pH [28] .  At pH 2, the 
conformational changes of Len during fibril formation were monitored and shown to be 
similar to those at pH 8 .  However, in contrast to pH 8 conditions, at pH 2 there was a 
delay between the conformational changes and the appearance of fibrils at high protein 
concentration (237 µM) [26] . 
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Figure 1.4. Fibril Formation of Len VL at pH 7 
P.O. Souillac et.al., Journal of Biological Chemistry (2002) Vol 277. 12657- 12665 
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This group explained the decrease in the rate of fibril formation at high protein 
concentrations at low pH as follows; the formation of oligomers ( off-pathway species) 
interacted with the intermediate essential for forming fibrils resulting in the formation of 
off-pathway intermediates [26] which delayed the formation of fibrils (Figure 1.5). The 
physiological significance of this model was explained by the fact that Len at higher 
concentrations ( despite its production of 50g/day) was not forming fibrils. This model 
could explain the basis of the action of Len in vivo systems where the high concentrations 
of Len in blood and kidneys remained as stable dimers and were excreted before they 
formed fibrils [26]. Because the light chain Len was excreted at levels of 50 g /day, it 
might be forming off-pathway intermediates according to this alternative way, which 
delays the formation of amyloid fibrils. The proposed schemes for Len fibril formation at 
pH 7 and pH 2 are explained in Figures 1.4 and 1.5 respectively. 
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Figure 1 .S. Fibril Formation of Len VL at pH 2 
P.O. Souillac et.al., Journal of Biological Chemistry (2002) Vol 277. 12666- 12679 
15 
Diagnosis and Treatment of AL 
The diagnosis of systemic amyloidosis requires the biopsy of the organs / tissues 
[8]. The most common method of analysis following tissue biopsy is the Congo red 
staining of tissue sections followed by microscopic evaluation under cross-polarized 
illumination [1]. Radiolabelling Serum Amyloid P- component (SAP), a biomolecule 
with high affinity for amyloid fibrils, with radioiodine is another technique for directly 
imaging amyloid deposits that gives information about the distribution of amyloid in 
tissues and/or organs in patients [1] [2]. In addition, chemical characterization of the 
amyloidogenic precursor protein by amino acid sequencing or immunohistochemistry is 
also important in understanding the type of the systemic amyloidosis, and to avoid 
misdiagnosis [8] [29]. 
The most common approaches for the treatment of AL amyloidosis as well as 
other systemic and local amyloidosis focuses on reducing the synthesis of amyloidogenic 
precursor protein [1] [2] [5] or promoting its clearance, as in the case of DRA where �2m 
accumulates in excessive amounts which might lead to amyloid deposition [16] [30]. 
There are also other types of suggested therapies including the stabilization of the native 
structure and preventing the formation of amyloidogenic intermediates or stabilizing the 
structures of partially folded intermediates and inhibiting their fibril formation [2]. This 
approach has been particularly successful in preventing TTR fibrillogenesis [20]. In 
addition, there are ongoing studies aiming to prevent the interaction of fibrils or precursor 
proteins with certain cofactors such as glycosaminoglycans (GAGs), apolipoprotein E 
(ApoE), or SAP [31] [32] [33]. 
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In AL amyloidosis, chemotherapy is a common method of treatment, which 
involves the non-specific destruction of plasma cell clones producing the pathological 
light chains. This is often followed by autologous stem cell transplantation. One of the 
drawbacks of this approach includes the chemoresistance of some patients and the high 
toxicity of the procedure [5] .  In addition, the response time is slow and patients with 
severe and rapidly progressive disease may not benefit from this approach [ 1 ]. Therefore 
alternative methods and drugs are also being evaluated for therapeutic efficacy: IDOX 
( 4 '-iodo-4 ' -deoxy-doxorubicin) is a drug which is known to interact not only with LC 
fibrils but also with TTR (V30M variant), A�, AA, and �2m fibrils [2] [5] [29] . The 
actions of this drug include the disaggregation of fibrils and inhibition of their formation. 
However, it is very toxic, its mechanism of fibril reabsorption is unknown and it appears 
to be effective only in patients with soft tissue amyloid deposits [29]. There are also other 
ongoing studies targeting the removal of amyloid fibrils or preventing their deposition in 
tissue. However some of these approaches such as synthesizing antisense 
oligonucleotides recognizing the CDR regions of LCs to inhibit the expression of VL 
mRNA have only been tried in in vitro models [34] . 
Active immunotherapy (immunization) was also considered as a method of 
treatment in AD patients, before adverse affects were observed in clinical trials. The 
preclinical experiments, before active immunotherapy was actually tried in humans, were 
performed using mice as an in vivo model. The aggregated form of A� ( 1-42) (ANl 792) 
was used to generate an immune response in mice. The antibody response generated 
against ANl 792 not only inhibited amyloid fibril formation but also resulted in the 
clearance of established amyloid plaques from the brain. This method also improved 
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cognitive behavior including memory loss in mice [35]. Phase I studies involving 
ANl 792 resulted in an anti- AP response and was shown to be non-toxic. However in a 
Phase II study, this immune response caused inflammation of the brain and spinal cord 
and its further usage was halted [36]. Although this vaccine was thought to induce 
antibodies that only recognized the plaque form of AP but not the soluble monomer form 
[36], a recent study have shown that this was not the case [3 7]. The immunization with 
AN 1792 in AD patients resulted in antibodies which were also recognizing the 
monomeric form AP. The fact that the antibodies recognize a linear epitope in the AP 
sequence in addition to the plaque conformation raises the possibility that the 
inflammation that occurred in some patients may be related to the cross-reactivity of this 
antibody. 
An alternative method to induce reabsorption of fibrils is passive immunotherapy 
[29]. This approach involves the generation of antibodies against only the fibrillar form 
of the protein. The aim of this method was to utilize antibodies that selectively bind 
fibrils and that could induce immune mediated disaggregation and clearance of amyloid 
deposits. 
One of the reasons for the lack of amyloid removal to the body is the absence of a 
stringent immune response against the amyloid deposits. In order to understand whether 
this immune response could be elicited, an in vivo experimental mouse model was 
developed [29]. Mice were injected sub-cutaneously with amyloid material extracted 
from spleen or liver of patients with AL amyloidosis. The resulting "amyloidomas" were 
resolved in untreated mice within 14-26 days post-injection by an immune mediated 
response to the xenograft that involved the generation of amyloid-reactive antibodies. 
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The amyloid resolution was shown to include three steps: 1) The binding of the antibody 
to the amyloid fibrils; 2) The attraction and activation of neutrophils by interaction of 
their Fey receptor to the Fe portion of the amyloid-bound antibody, and; 3) Enzymatic or 
chemical proteolysis of the amyloid through neutrophil-derived endopeptidases and 
release of free radicals. Therefore, it was demonstrated that amyloid dissolution was 
possible, but amyloid deposits were generally irreversible in AL patients, due to the 
absence of opsonizing antibodies. To examine this mechanism further, a panel of V L -
reactive mAbs, generated using heat aggregated and fibrillar immunogens were evaluated 
in vitro for their ability to bind to AL amyloid fibrils and extracts. Among these 
antibodies, one lgGl antibody designated 11-1F4, was shown to recognize light chain 
fibrils regardless of the K and A. subgroup of the VL. Furthermore, this antibody, was 
found capable of binding to amyloid fibrils formed from different amyloidogenic proteins 
such as lysozyme, amyloid A, ApoAl ,  Abeta (1-40), and TTR isolated from patients [29]. 
Since it recognized AL amyloid fibrils regardless of their subgroups and fibrils generated 
from different soluble precursor proteins, it was thought to recognize a common epitope 
within these fibrils. Determining the structure of the conformational epitope, which is 
recognized by l 1-1F4, is important for future therapeutic purposes and drug design, for 
diagnostic and prognostic purposes, and a goal of this thesis. 
Many studies have shown that antibodies raised against the denatured 
recombinant or fibrillar form of amyloidogenic proteins, or to a region of the protein 
exposed during fibrillar transition, serve as important tools for understanding the 
mechanism of fibril formation [30] [38] [39] . This is, in turn, can provide new diagnostic 
or therapeutic tools for reducing or inhibiting the process. Therefore these antibodies 
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represent important clinical and preclinical tools for the treatment and diagnosis of 
amyloid diseases. 
One of the drawbacks in the development of these antibodies is the possibility of 
cross-reactivity with the soluble form of the amyloidogenic proteins instead of only 
recognizing the pathological form. Their reactivity with the soluble form may have an 
adverse effect on the function of the protein that may be involved in critical biochemical 
pathways [38]. Some studies have identified such characteristics [40]. 
Three mAbs (IgGl K  lF l  l ,  7B6 and 14H3) raised against the fibrillar form of �2m 
were shown to recognize the native form of �2m (associated with the major 
histocompatibility complex type I) [30]. These mAbs were initially aimed to be used for 
studying in vitro fibril formation from �2m and were shown to recognize different 
epitopes in the �2m sequence. The region where one of these antibodies (14H3) binds to 
�2m, overlapped with the region where �2m associates with the MHC Class I. This 
antibody was also shown to inhibit �2m fibril formation in vitro consistent with the fact 
that the epitope of 14H3 may be important in self assembly process of �2m when forming 
fibrils. The other two epitopes, recognized by 1 F 1 1  and 7B6, were not considered to be 
important for fibril formation as they did not inhibit the fibrillogenesis of �2m [30]. 
Although the results of this study were promising and contributed to an understanding of 
the regions of �2m associated with fibril formation, the recognition of both the fibrillar 
form and the native form of �2m by all of these antibodies showed their non-specificity. 
Many studies have also focused on generating antibodies against the prion protein 
(PrP), of which there are two forms, the cellular prion protein (PrPc - nonpathological), 
and the scrapie form (PrPsc - pathological). The cellular form of this protein is mainly 
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composed of an a-helical structure and the pathological form mainly consists of a �-sheet 
structure [41 ]. The conversion of the PrPc to PrPsc form is thought to play an important 
role in the amyloid fibril formation from this protein, which results in transmissible 
spongiform encephalopathies (TSEs) such as bovine spongiform encephalopathy and 
Creutzfeldt-Jakob disease (CJD) [39]. Certain regions of the human PrP encompassing 
residues 106-126 and the tyrosine-tyrosine-arginine (Tyr-Tyr-Arg) repeats are thought to 
become exposed during the conformational transition from PrPc to PrPsc [38] [40]. One 
of the antibodies raised against the linear, cryptic epitope Tyr-Tyr-Arg was found to 
differentiate between the pathological and benign forms of PrP [38]. The antibody raised 
against the PrP 106- 126 was found to recognize both forms of PrP and inhibit fibril 
formation and cytotoxicity [ 40]. 
In another study two antibodies were generated against a mutant form of TTR that 
was thought to have a conformation similar to that of amyloidogenic TTR [42]. These 
antibodies were found to bind amyloid from TTR patients ( ex vivo) and synthetic TTR 
mutants with the amyloidogenic fold, but not the wild type or TTR mutants having a 
conformation similar to the wild type TTR. These data provided further evidence that 
amyloidogenic proteins can access a unique conformation during amyloid fibril 
formation. 
The common Cross-� structure of amyloid fibrils suggests a similar mechanism 
for their formation and perhaps related conforma�ional changes in the precursors when 
forming fibrils [43] [44]. Conformation-dependent antibodies serve as important tools for 
mapping epitopes on these non-native precursors and can play a role in determining the 
mechanisms of aggregation, the nature of the cytotoxicity and the fibril structure [ 45] 
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[46]. In addition, critical regions of the amyloidogenic protein required for fibrillogenesis 
can be mapped. [46]. There are several examples of antibodies that recognize specifically 
a certain form of the amyloid-associated aggregates [45]. For example, the M16  
polyclonal antibody has been produced against the aggregated form of the Ap. This 
antibody only recognized soluble oligomers or the fibrillar state but not the monomeric 
AP precursor. In addition to reagents that bind non-native precursors, fibrils and 
pathogenic aggregates, another class of antibodies exist that react with many types of 
fibrils irrespective of their precursors. This class of antibodies includes WO 1 and W02 
that belong to the IgM class, were generated against AP (1 -40) fibrils [47] and were 
subsequently shown to also bind transthyretin (TTR), P2-microglobulin (P2m), 
polyglutamine (PolyQ), 16 light chain, and IAPP fibrils. These antibodies, even in the 
presence of excess amount of soluble AP ( 1 -40) and the non-fibrillogenic F19T mutant of 
AP (1 -40) were capable of strongly binding to AP(l -40) fibrils [47]. Binding of these 
antibodies was not observed using collagen and elastin as the substrate. Such studies not 
only suggested that these reagents recognized a common epitope on amyloid fibrils, but 
also that the amino acid sequence of the amyloidogenic proteins was not a determinant of 
the fibril-antibody interaction. 
Similar results have been reported for the l l - 1F4 mAb that recognizes amyloid 
fibrils generated from both 1C and A light chains in addition to the amyloid fibrils formed 
from non-light chain derived proteins [29]. 
The goal of this thesis was to characterize the conformational epitope recognized 
by 1 1 - 1F4, using the 1e4 Len light chain as the model protein and to further elucidate the 
functionality of the regions recognized by this clinically relevant fibril-reactive antibody. 
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Chapter 2. Materials and Methods 
Peptides and Other Reagents 
Len 1 -22, as well as the two mutated forms of the peptide (P8A and PSS Len 1 -
22) were purchased from Sigma or Keck Biotechnology Center. All the other peptides 
corresponding to different regions of the Len V L domain were purchased from the Keck 
Biotechnology Company. The sequences, molecular weights, and pl values of each 
peptide are shown in Table 2. 1 (For the sake of simplicity, P8A Len 1 -22 and PSS Len 1 -
22 will be referred to as P8A and PSS throughout the text). The primary (1 ° ) antibody 
used in Eu +3 -linked immunoabsorbant assays (EuLISA) experiments was the murine 
monoclonal antibody (mAb) l l -1F4, originally generated using as an immunogen the 
thermally denatured form of Len V L domain, having the characteristics of amyloid fibrils 
[29]. The initial stock solution of l l - 1F4 was kept in a PBS solution at pH 7.4, at 
concentration of 0.59 mg/ml. The secondary (2°) antibody used in EuLISA was a 
biotinylated goat anti-mouse IgG (Goat X Ms Ab) obtained from Sigma (St. Louis, MO). 
Bovine serum albumin (BSA) was purchased from Sigma. Tween 20 (Enzyme grade) 
used in the EuLISA wash and assay buffers was purchased from Fisher Scientific. Eu +3 -
labelled streptavidin and the enhancement solution were purchased from Perkin-Elmer. 
The 96-well high- and low- binding microtiter plates were purchased from Costar. a -
chymotrypsin used in the limited proteolysis experiments, was purchased from MP 
BioMedicals. For solubulizing peptides, trifluoroacetic acid (TF A) and 1 ,  1 ,  1 ,3 ,3 ,3 -
hexafluoro-2-propanol, 99.5 + % (HFIP) were purchased from Applied Biosystems and 
Acros Organics, respectively. 
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Table 2.1. Amino Acid Sequence and Calculated Physical Properties of the 1e4 Len­
derived N-terminal Synthetic Peptides 
Peptide Sequence pl Molecular 
Weight (Mwt) 
Len 1 -22 DIVMTQSPDSLA VSLGERA TIN 4.0 23 17.603 Da 
P8S Len 1 -22 DIVMTQSSDSLA VSLGERA TIN 4.0 2307.565 Da 
P8A Len 1 -22 DIVMTQSADSLAVSLGERATIN 4.0 229 1 .566 Da 
Len 1 - 1 3  DIVMTQSPDSLA V 3 .6 1375. 563 Da 
Len 5- 15  TQSPDSLA VSL 3.8 1 1 1 7.222 Da 
Len 5-22 TQSPDSLAVSLGERATIN 4.4 1 859.024 Da 
Len 1 -30 DIVMTQSPDSLA VSLGERA TINCKSSQSVL 4.6 3 1 50.580 Da 
Len 1 3-24 VSLGERATINCK 8 .2 1290.507 Da 
Len 1 - 1 8  DIVMTQSPDSLA VSLGER 4.0 1 9 1 8 . 1 56 Da 
Len 1 8-30 RA TINCKSSQSVL 9.5 1406.627 Da 
Len 22-46 NCKSSQSVLYSSNSKNYLAWYQQKP 9.4 2924. 245 Da 
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Solubilization of Peptides and Preparation of Fibrils 
Peptides were disaggregated and solubulized using the following TF A / HFIP 
protocol [ 48]. Peptides were disaggregated by dissolving in a solution of 500 µ1 TF A and 
500 µ1 HFIP per mg of peptide for IO  min at RT. The solvents were removed by 
evaporation under a stream of argon gas and the peptides resolubilized using only HFIP 
(750 µ1 per mg of peptide). The peptide solution was aliquoted into glass tubes at no 
more than lmg/tube to avoid re-aggregation and kept in the 37 °C incubator for 30 
minutes. HFIP was again removed by evaporation under argon. The peptides were further 
dried by placing the tubes in a speed vacuum drier (Savant Speed -Vac) at 37 °C for 10-
15 minutes. Before use, peptides were rehydrated, based on their pl values, using either 
dH20 or lmM NaOH in PBS. If the pl of the peptide is approximately the same as the pH 
of the solution, the peptide will have a zero net charge, thus increasing the chance of its 
aggregation. Len 1-22 peptide appeared to form fibrils when kept in a solution of PBS; 
therefore it was rehydrated in pure dH20. The peptide solutions were centrifuged at 
13,000 x g for 10 minutes and filtered through a 0.22µm pore-sized filter (millipore). For 
fibril formation assays, the peptide solutions were filtered into glass tubes, then put in an 
orbital shaker at 37 °C with shaking at 225 rpm (Queue Orbital Shaker) for at least 1 
week. Fibril formation was monitored using Thioflavin T (ThT) (see below). 
Calculating Peptide Concentrations 
Peptide concentrations were calculated using the Micro BCA TM Protein Assay Kit 
(Pierce). This method uses BCA (bicinchoninic acid) which detects Cu+ 1 formed when 
Cu +2 is reduced by protein in an alkaline environment. Two molecules of BCA chelate 
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one Cu +1 which results in the formation of a purple-colored reaction-product. This water­
soluble complex exhibits a strong absorbance at 562 nm proportional to the protein 
concentration in solution (Micro BCA ™ Protein Assay Kit protocol). Peptide stock 
solutions were diluted ( 1 :  1 0) using PBS. The BSA stock solution (2 mg/ml) use to 
generate the standard curve was diluted ( 1 : 1 0) using PBS and this solution was used as a 
standard. These solutions of BSA and peptide were further diluted in 96-well microtiter 
plates. The total volume in each well after the dilutions was 1 50 µ1. The BCA solution 
was prepared as described in the Protein Assay Kit and 1 50 µ1 added to each well. The 
plates were incubated in the 37 °C incubator for 1hr and then absorbance readings were 
taken at 562 nm using the spectrophotometer (Spectra MAX plus - Molecular Devices). 
The standard curve was prepared from standard BSA containing wells, and the 
concentrations in the peptide solutions were determined using the standard curve. 
Thioflavin T Binding Assays 
Thioflavin T {ThT) is a dye, commonly used to monitor fibril formation and to 
determine the presence of fibrils in solution, ThT binds to fibrils, which results in a 
dramatic increase in its fluorescence emission intensity at 490 nm when excited at 450 
nm ([4]). In all the experiments regarding the formation of fibrils, ThT binding assays 
were used. To measure the presence or absence of fibrils in solution, an FL600 
Fluorescence Microplate Reader (Biotek) was used equipped with excitation and 
emission cut-off filters of 430 nm and 480 nm. Fibril formation assays, were performed 
using a fluorometer (Aminco Bowman Series 2- Luminescence Spectrometer) measuring 
the increase in the ThT emission at 490 nm with the exciation at 450 nm. In these 
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experiments, a ThT stock solution of lmM in dH20 was prepared and used for all the 
experiments. To detect fibrils in solution, a 10 µI aliquot of peptide (43µM) was mixed 
with 3µ1 of lmM ThT solution and made up to 100 µl with PBS in 96- well low- binding 
microtiter plates. For fibrillogenesis kinetic assays, stock peptide solutions were diluted 
to a final concentration of 50 µM in a total volume of 2.5 ml of PBS containing 30µM 
ThT. The solution made up in a stoppered plastic cuvette, was placed in the fluorometer, 
stirred with a stir bar at l rps for 18 hrs and the increase in the ThT fluorescence measured 
continuously. 
Electron Microscopy 
Precipitates were applied to Formvar carbon-coated copper grids, air-dried, 
stained with 1 % phosphotungstic acid, and viewed with a Hitachi H-600 electron 
microscope. 
11-1F4 Europium (Eu+3)-linked lmmunoabsorbant Assay (EuLISA) 
The peptides or the fibrils in solution were coated on 96- well, high- binding 
microtiter plates at a final concentration of 8 µg /ml, and incubated overnight at 3 7°C. 
The plates were washed once with the wash buffer {PBS, 0.05% Tween), to remove 
loosely bound material. Each well on the plate was blocked with 200µ1 of a solution 
containing 1 % BSA in PBS by incubating at 37°C for 1 hr. In the next step, the solution 
of the primary (1 °) antibody, 11-1F4 prepared in assay buffer (1 % BSA, PBS, 0.05% 
Tween) to a final concentration of O. l µM was added to the wells (100 µI /well). The 11-
1F4 mAb was diluted across the plate, with a starting concentration of 0.1 µM and a 
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dilution factor of (1 :2) for each column. The plates were then incubated at 37° C for 1 
hour after which they were washed with wash buffer twice, to remove unbound 11- 1F4. 
The 2° antibody (Goat X Ms Ab) diluted 1 :5000 in Assay buffer was added (100 µI /well) 
to the wells and the plates were incubated at 3 7° C for 1 hour. The plates were washed 
twice with wash buffer and the wells treated with Eu+3-labelled streptavidin solution 
(1: 1000 dilution in PBS) and incubated at 37° C for a further 1 hour. To develop the time­
resolved fluorescence signal, enhancement solution was added to each of the wells and 
the fluorescence emission readings were taken using a spectrofluorometer (Wallac 
VICTOR3 TM 1420 Multilabel Counter (Perkin Elmer). The Europium fluorescence as a 
function of different concentrations of 11-1F4 was plotted and used to determine the 
binding of 11-1 F 4 to fibril-adsorbed peptides and fibrils. 
Limited Proteolysis Experiments 
HPLC Conditions for Peptide Purification 
10 mg of Len 1-22 peptide (Keck Biotechnology Center) or P8A (Sigma) were 
solubulized in 6M GdnHCl. Following peptide solubulization, the peptides were purified 
by High Pressure Liquid Chromatography (HPLC) {Perkin Elmer Model 200) using a 
mobile phase of 0. 1% TFA and a 7 -70% acetonitrile/ water (v/v) linear gradient at a flow 
rate of l mVmin on an Aquapore 300A C8 reverse-phase column (210 X 4. 6 mm). A 45 
minute gradient was used for purification. The fractions were collected manually, 
gathered, and the solvent removed using the speed vacuum overnight at 37°C. 
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Proteolytic Digestions for Peptides 
The purified peptides were disaggregated using the TF A/HFIP protocol and 
rehydrated in 80 mM Tris-HCI buffer (pH 7.61) to give a final stock concentration of -­
lmg/ml peptide solution. The concentration of the purified peptide was determined by 
Micro BCA ™ Protein Assay Kit (Pierce). An aliquot of 100 µ1 from this stock was 
analyzed by Electrospray Ionization Mass Spectrometry (ESI-MS) to monitor the 
integrity of peptide in solution. Another 100µ1 was from this stock was used for the 
digestion experiments. For proteolytic digestion, a-chymotrypsin (Sigma) was added to a 
solution of purified monomer at a weight ratio of 1: 10 ( enzyme to protein) and kept in the 
incubator at 3 7°C for up to 2 hours. The first aliquot was removed from this solution after 
5 minutes, and further aliquots were removed every 20 minutes thereafter. The reaction 
was quenched by adding 1 % TF A to the Len l -22 and P8A peptide solutions. 
Electrospray Mass Spectrometry Analysis 
A PE-SCIEX Type 150 EX (Perkin Elmer) single quadrupole electrospray ionization 
mass spectrometer (ESI-MS) was used to identify peptide fragments of Len l -22 and 
P8A, after digestion with chymotrypsin at various time points. The "quenched" aliquots 
were first passed over a rever�e phase HPLC apparatus before being infused into the MS 
at a flow rate of 5µ1/min using a Harvard Apparatus Model 11 syringe pump. 
Experiments were performed in the positive ion mode with a capillary voltage of 4.8kV, 
alternating mode orifice voltage 31 V, and a ring voltage of 230V. The source temperature 
was maintained at 25°C. All spectra were acquired in the multichannel accumulation 
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mode over a mass range of 500-2500 Da at 333Da/s. Spectra were analyzed using the 
Biomultiview program provided by the system manufacturer (PE-SCIEX, Perkin Elmer). 
Limited Proteolysis Experiments for Len 1-22 and P8A Fibrils 
Fibril Synthesis 
The fibrils were generated from peptides as previously described. Before the 
fibrils were produced, the purity of the starting material was confirmed by ESI-MS 
analysis. 
Proteolytic Digestion of the Fibrils 
Len 1 -22 and P8A fibrils were collected by centrifugation, washed with 80 mM 
Tris-HCl buffer (pH 7.6 1)  to yield a concentration of - l mg/ml and the integrity of the 
peptides confirmed by ESI-MS. For proteolytic digestion, a-chymotrypsin (Sigma) was 
added to Len 1 -22 or P8A fibril solution at a weight ratio of 1 :  1 0  ( enzyme to protein) and 
the solutions kept in the incubator at 3 7°C for 2 hours. The first aliquot was removed 
from the mixture at the end of 5 minutes, and further aliquots were removed every 20 
minutes thereafter. As above, the reaction mixture was quenched by adding 1 % TF A 
solution. The digested fibril solutions were subjected to TF A/HFIP protocol as described 
above, in order to solubulize the fibrils, as the insoluble fibrils clogged the capillary 
column and resulted in ambiguity of the mass spectra. After the TF A/HFIP protocol, 
proteolytic fragments of fibrils were solubulized in 30 µl of 0. 1 % TF A solution and 
analyzed by HPLC coupled to ESI-MS as described above. 
Electrospray Mass Spectrometry Analysis 
This Technique was performed as described above. 
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Chapter 3. Determining the Structural Difference between Len 1-22, 
P8A and P8S Monomer by 11-1F4 Binding Assays 
Abstract /Rationale 
1 1 - 1F4 is a mAb generated against the thermally denatured VL region of a 1e4 light 
chain isolated from a patient-Len with multiple myeloma but no signs of AL amyloidosis. 
This antibody reacts with all types of AL fibrils regardless of their A or 1e subgroups, 
suggesting that it recognizes a common �-pleated sheet conformational epitope [29]. In 
this study, peptides relating to known regions of the Len VL domain to which 1 1 - 1F4 
bound were immobilized on the 96 well plates, and the affinity for each peptide tested 
using the EuLISA from which EC5o values were calculated (O'Nuallain, et al. 2006 in 
preparation). In addition, 1 1 - 1F4 binding affmity was tested for P8A- and PSS­
substituted forms of Len 1 -22 in order to examine the effect of a single amino acid 
substitution on the conformation of Len 1 -22. The proline 8 (Pro8) in the Len 1 -22 
sequence is considered to be critical for forming the conformational epitope on Len 1 -22, 
that is recognized by 1 1 - 1F4. P8A and P8S mutations are discussed in terms of how they 
would alter the conformational epitope. The aim of these experiments was to provide 
insights into the structure of the 1 1 - 1F4 binding in the Len 1 -22 peptide sequence. 
The binding affinity of 1 1 - 1F4 to peptides corresponding to various regions of the 
Len VL domain N-terminal was performed previously (O'Nuallain, B and Allen, A) using 
EuLISA (Fig. 3 . 1 ). Since 1 1 - 1F4 was originally generated against the denatured form of 
the Len V L domain and not the native form, its binding affinity to the denatured forms of 
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Figure 3.1 11-1F4 Binding to Peptides Derived from Different Regions of Len VL 
Domain (O'Nuallian et al. 2006, in preparation) 
these peptides was established. To determine the EC5o ( concentration of half maximal 
binding), dilutions of the primary antibody 11-1 F 4 were made from a starting 
concentration of 100 nM and the EuLISA performed as described in Materials and 
Methods. 
Using these assays 11-1 F 4 was previously shown to bind to Len V L and peptides 
corresponding to different regions of Len VL is shown in Figure 3.1. 
A brief summary of the findings of O'Nuallain et al. will follow, as this relates 
specifically to the data and interpretation presented in the Results Section. It has been 
demonstrated that the 11-1F4 binding site (epitope) was localized to the N-terminal 
region of the Len VL domain. 1 l -1F4 bound equally well to the intact Len VL domain and 
the first twenty two N-terminal residues (Len 1-22) with high affinity; ECso value of 
(-1.95 x 10- 10). Although 11-1F4 had a similar affinity for the first thirty residues (Len 1-
30), the minimal regit>n for highest binding affinity determined in these studies, was 1-22. 
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11-1 F 4 binding was shown to decrease when the residues 14-22 were absent, 
demonstrated by an increase in the EC50 value (1.3 x 10-8) for the Len 1-13 peptide. The 
11-1F4 binding decreased similarly when the first four N-terminal residues were omitted, 
(Len 5-22) although the ECso value was still in the same range as that for Len 1-13. Len 5-
15 lacking both the N and C terminal regions on the minimal region, was found to be 
essentially not recognized by 11-1F4 (O'Nuallain et al. 2006 in preparation). According 
to these data, both N and C terminal residues of the region encompassing the first 22 
residues on the Len V L domain, were shown to be essential for high affinity binding of 
11-1F4. However understanding how these residues are involved in 11-1F4 recognition 
requires further studies. The ECso values for each peptide are shown in Table 3.1 (Results 
and Discussion Section). 
Results and Discussion 
Many antibodies recognize their antigen in a conformation-dependent manner 
[45] [46] [47]. It was previously demonstrated that l l -1F4 bound to the denatured form 
of the Len V L domain, and not the soluble form. This indicated that 11-1 F 4 was 
recognizing a conformational epitope on the denatured form of the Len VL domain [29]. 
According to the results obtained previously here, 11-1F4 recognized a conformational 
epitope in the first 22 residues where both the 1-4 and 13-22 residues were important for 
the binding. One of the possibilities for the conformational epitope involves the 
following; the sequence of Len 1-22 contains a proline residue at position 8, which may 
generate a P-turn, bringing the N and C-terminal residues close in proximity. 
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Table 3.1 The EC50 Values of 11-1F4 for Peptides Corresponding to Different Regions of 
the Len N-terminal Region 
Peptides ECso values 
(M) 
Len 1-30 1.95 X 10-JU 
Len 1-22 1.95 X 10-IO 
Len 1-13 1.25 X 10-lS 
Len 5-22 2.5 X 10-8 
Len 5-15 5 x  10-is 
Len 13-24 > 5 X 10-7 
Len 18-30 > > 5 X 10-7 
Therefore 11-1F4 may recognize Len 1-22 in a "bent" conformation. Another possibility 
is that the N and C-terminal regions of two different Len 1-22 peptides interact with each 
other in a linear conformation, where 11-1 F 4 recognizes these regions of the two peptides 
in close proximity (Figure 3 .2; from O 'Nuallain et al. 2006 in p ). 
Comparison of the 11-1F4 binding affinity to Len 1-22 and its mutated forms 
(P8A and P8S) is shown in Figure 3.3. The difference in the Eu+3 fluorescence emission 
demonstrated the difference in the 11-1F4 binding to the native and the mutated forms of 
Len 1-22. The ECso value for P8A was > 2.5 x 1 0-1, and this value could not be 
determined for P8S as it was > 1 x 10-6. These data demonstrated that at these 
concentrations of 11-1F4, the binding affinity for P8A and P8S was negligible compared 
to that of Len 1-22. 
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Figure 3.2 Hypothesized Structure for the Conformational Epitope of Len 1-22 
Recognized by l l -1F4 a) Tum Conformation (N and C terminals of 1-22 Peptide in 
Close Proximity) b) N and C Terminal Interaction in a Linear Conformation (from 
O'Nuallain et al. 2006 in preparation) 
� ::: l 
� 1 20 0 
f 1 00 -" 
§ 80 ·a. e so 
::, 
W 40 
20 
0 
6 7 8 
-log[1 1 -1 F4] M 
9 1 0  
Figure 3.3 Comparison of 1 1 -1F4 Binding to Len I -22 (•), P8A (+) and P8S (•) 
Monomer 
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This data support the first hypothesis and raised the question of how a single amino acid 
substitution in the sequence of Len 1-22 could so dramatically alter the 11-1F4 binding to 
these peptides. 
Previous studies had shown that recognition by antibodies of the denatured forms 
of the peptide or protein depended more on the conformation of peptide/proteins than the 
amino acid sequence [29] [47]. Although the primary amino acid sequence is important in 
determining that conformation [ 49], single amino acid substitutions may alter the 
conformation according to where they are positioned in the sequence [50] [51]. In 
addition, the occurrence of some amino acids such as the structure breaking proline in 
secondary structures such as P-sheets and a-helices, is very low compared to other amino 
acids [49]. There are two main reasons for this lower occurrence. In the structure of 
proline, the nitrogen atom is a part of a rigid ring and the rotation around the N-Ca bond 
( cp-phi) is restricted; this restriction is incompatible with the peptide bond geometries of 
both "P-sheets" and "a-helices". In addition, the same nitrogen atom is incorporated in 
the ring structure, therefore the amide hydrogen cannot contribute to the H-bonding 
network of "fl-sheets" or "a-helices". However proline is well accommodated in another 
prominent secondary structure which is the "P-turn" [ 47] [ 49]. 
11-1F4 was initially generated against the thermally denatured form of acidified 
Len V L domain and this denatured form was shown to have the characteristics of amyloid 
fibrils [14] [29]. Cross-P sheet is the characteristic secondary structure of amyloid fibrils. 
This antibody was shown to recognize an epitope common to P-pleated structure of light­
chain related fibrils [29]. 
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As described here, 11-1 F 4 was also shown to bind to the denatured forms of Len 
1-22 and the Len Vt domain with high affinity. Therefore the binding is likely to occur 
by recognizing a P-sheet structure in the denatured form of the Len V L domain 
encompassing the residues 1-22. 
The amino acid sequence of the native and the mutant peptides of Len 1-22 
differed only in the Pro 8 position. Given that a single amino acid substitution created 
such a decrease in the 11-1 F 4 binding affinity, the epitope recognized by 11-1 F 4 is likely 
to be conformation-dependent rather than sequence-dependent. In addition, this 
demonstrated the importance of the Pro8 for 11-1F4 binding in the Len 1-22 sequence. 
These data imply that Pro8 may be involved in a "P-turn" in Len 1-22 peptide (and VL), 
bringing regions 1-4 and 14-22 closer in proximity. In contrast to a proline residue, 
alanine is not well accommodated in a "P-turn" region [49]. Therefore the substitution of 
Pro8 by Ala, most likely would disturb the proposed P-turn structure and therefore the 
conformation of Len 1-22 recognized by 11-1F4. Although serine is almost as commonly 
found as the Pro residue in a "P-turn" region [49], the conformation which 11-1F4 
recognizes was lost in the P8S mutant. 
These experiments illustrated how a single amino acid substitution within the 11-
lF  4 binding site could alter the 11-1F4 affinity by hampering the ability of this region to 
form a novel P-turn configuration. 
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Chapter 4. Characterizing the Fibrillogenic Regions of the Len V L 
N-terminal 
Abstract / Rationale 
The aim of these experiments was to elucidate which regions on the Len V L N­
terminal were fibrillogenic and compare the rate of their fibril formation. The same 
peptides used for 1 1 -1  F 4 binding assays were used in order to correlate the 
fibrillogenicity of this region with the 1 1 - 1F4 binding. ThT was used in order to monitor 
the fibril growth from these peptides. Notably, we found that only the peptides (Len 1 -22 
and Len 1 -30) for which 1 1 - 1F4 had an increased binding affinity, were capable of 
forming fibrils. 
In Chapter 3, 1 1 - 1F4 binding affinity to Len 1-22 was shown to decrease by P8A 
or P8S substitutions. The change in the binding affinity of 1 1 - 1F4 was explained by the 
change in the conformation of Len 1 -22 due to these mutations. 
In the experiments presented in this Chapter, P8A and P8S were also used in in 
vitro fibril formation and the "rate of fibril" formation assays, in order to examine the 
effect of this conformational change on the fibril forming capacity of Len 1 -22. The 
mutant peptides were shown to form fibrils eventually, but with a longer lag time as 
compared to Len 1 -22. The importance of the N and C-terminal regions on Len 1 -22 in 
forming fibrils, and the possible role of Pro8 in generating a tum structure bringing N and 
C terminal regions closer in proximity in the Len 1 -22 fibril structure are discussed. 
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Results and Discussion 
The Len V1 domain was shown to be fibrillogenic in vitro, with low 
concentrations of GdnHCl [14]. In the experiments presented here, an in vitro fibril 
formation assay [52] was used to show which regions in the N-terminal Len V1 domain 
were potentially involved in amyloid fibril formation. Peptides corresponding to different 
regions of the N-terminal Len V1 domain, in addition to P8A and P8S, were 
disaggregated using the TFA/HFIP protocol (Materials and Methods), suspended in PBS, 
and kept in the orbital shaker at 3 7 °C for 7-14 days. The fluorescent dye Thioflavin T 
{ThT), was used to monitor fibril formation over this time. In addition, the rate of fibril 
formation of these peptides was compared by monitoring the increase in the ThT 
fluorescence continuously over an 18 hour period. 
Previous experiments have shown that 11-1F4 recognized an epitope on the Len 
V1 and other light chain fibrils [29]. The goal of the in vitro fibril formation assays was to 
i) determine whether the same peptide regions on the Len V 1 domain that bound to 11-
1 F 4 were also fibrillogenic ii) compare the relative rates of fibrillogenesis of these 
peptides and, iii) to observe how the P8A and P8S substitution affect fibril formation. 
The results of the experiments for determining the fibrillogenic and non 
fibrillogenic regions on the 11-1F4 binding N-terminal Len V1 are shown in Table 4.1. 
According to these data, only the Len 1-22 and Len 1-30 peptides were capable of 
forming fibrils. The first four N-terminal residues and the last seven C-terminal residues 
were shown to be essential in fibril formation of Len 1-22, shown by the incapability of 
Len 5-22 and Len 5-15 to form fibrils. Len 1-18 and Len 1-13 were found to form 
amorphous aggregates, but lacked the ability to form fibrils according to electron micros-
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Table 4.1 Non-fibrillogenic and Fibrillogenic Regions of the Len VL Domain 
Len K4: DIVMTQSPDSLA VSLGERA T INCKSSQSVL. . . . . . . . . . . . . . . . . . . . . . . . . . . .  
N on-fibrillogenic 
Len (1 - 18):D-------------------------------R } aggregate Len ( 1 - 1 3) :D---------------------V 
Len (5-22) : T-----------------------------N 
Len (5- 1 5) :  T-----------------L 
Len ( 1 3-24) : V-------------------K 
Len ( 18-30): R----------------------L 
Len (22-46) : NCKSSQSV L YSSNSKNYLA WYQQKP 
F ibrillogenic 
Len ( 1 -22):D-----------------------------------N 
P8A: D-------------------------------------N 
P8S: D-------------------------------------N 
Len ( 1 -3 0) :D------------------------------------------------------L 
copy results (Figure 4. 1 ). The peptides corresponding to the C-terminal region of Len 1 -
30 (Len 13-24 and Len 1 8-30) were also incapable of forming fibrils, providing further 
evidence for the importance of the N-terminal region of this domain for fibril formation. 
The peptide corresponding to the 22-46 region did not form fibrils. 
In previous experiments (Chapter 3), 1 1 - 1F4 was shown to have the highest 
binding affinity for the N-terminal region (encompassing the first 22 residues) of the Len 
VL domain. In addition, the antibody was shown to bind to Len 1 -22 in a conformation 
dependent manner, which was inhibited by a single amino acid substitution. Since the 
conformation of the peptide recognized by 1 1 - 1 F4 was disturbed due to mutation at this 
position, one of the goals of these experiments was to see whether such a mutation in Len 
1 -22 also altered the fibril formation capacity. 
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Figure 4.1 Electron Microscopy Images for Len 1-18 and Len 1-13 Amorphous 
Aggregates. The amorphous aggregates were obtained from 1 mg/ml peptide solution 
under the fibril formation conditions described in Materials and Methods 
a) Len 1-18 b) Len 1-13 
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Surprisingly both P8A and P8S gave a ThT positive signal similar to Len 1-22 indicating 
the formation of fibrils ( discussed in more detail in Chapter 5). Therefore the rate of fibril 
formation of Len 1-22, P8A and P8S were compared to observe whether the rate of fibril 
formation was altered due to Pro8 substitution in Len 1-22. The other nonfibrillogenic 
peptides, were also used in these experiments as controls (Figure 4.2). According to the 
results, only Len 1-22 showed an increase in the ThT fluorescence in 18 hours, indicating 
the formation of fibrils. These results not only confirmed other peptides were 
nonfibrillogenic, but also that P8A and P8S fibril formation occurred at a significantly 
slower rate with a longer lag time as compared to Len 1-22. 
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- Len 1 -1 8  peptide 
Len 1 -1 3  peptide 
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- P8A Len 1 -22 peptide 
Figure 4.2 Rate of Fibril Formation of Peptides Derived from Different Regions of Len 
V L Domain and Mutated Len 1-22 Peptides 
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Although the exact mechanism is not known, in vitro . studies suggest a general 
mechanism for amyloid fibril formation [3] [19]. The first step in the formation of fibrils 
from amyloidogenic proteins, is the formation of partially folded /unfolded conformation. 
This enables specific intermolecular interactions such as electrostatic and hydrophobic 
interactions, as well as hydrogen bonding between two partially folded/unfolded 
conformations [44], which lead to the formation of protofilaments. The interaction of 
protofilaments results in the formation of fibrils [3]. 
Peptides and proteins capable of forming fibrils in vitro and in vivo, show little or 
no sequence homology [3] [47]. Therefore the specific interaction of residues leading to 
amyloid fibril formation of these different peptides/proteins is not clearly understood 
[53]. The frequent occurrence of aromatic amino acids in fragments of amyloidogenic 
proteins raised the possibility that 1t-1t interactions are involved in fibril assembly [54]. 
However Len 1-22 contains no aromatic amino acid in its sequence, therefore this is 
unlikely to contribute in this case. The N and C-terminal regions of the 1-22 peptide, 
which are both essential for fibril formation, contain amino acids with polar, nonpolar 
and charged side chains. 
According to our results, the peptides corresponding only to the C-terminal region 
(18-30, 15-22, 13-24) remained soluble even after 14 days of shaking at 37°C. This 
indicated that interaction of the C-terminal region of the Len 1-22 peptide with another 
region in the sequence was important for its fibril formation. The peptides lacking the N­
terminal only (Len 5-22) and both the N- and C-terminal regions (Len 5-15) both 
remained soluble after 2 weeks. This indicated that interactions of N- and C-terminal 
regions within the same Len 1-22 molecule or perhaps between two Len 1-22 molecules 
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were important for the formation of fibrils. The interaction of N and C-terminal regions is 
possible through the hydrophobic interactions of the nonpolar residues found in both 
regions, and hydrogen bonding between the peptide backbone of two Len 1 -22 molecules. 
The importance of the Pro8 residue in maintaining the conformational integrity of 
the Len 1 -22 peptide was shown in the 1 1 - 1F4 binding assays (Chapter 3). In the 
experiments presented here, the effect of the conformational change due to Pro8 
substitution by Ala or Ser on the Len 1 -22 fibril formation capacity was tested by the in 
vitro fibril formation assays. P8A and PSS were shown to form fibrils eventually, 
therefore the alteration in the structure by the Pro8 residues substitution was shown only 
to affect the rate of the fibril formation. Proline residues introduce kinks in polypeptide 
chains and anchor �-turn motifs [49]. According to our hypothesis, Pro could be involved 
in bringing the N- and C-terminal regions closer in proximity favoring the interactions of 
both regions within the native Len 1 -22 molecule. The interaction within the same Len 
molecule, resulting in a turn structure, seemed to have formed a favorable conformation 
for forming fibrils (Figure 4.3 a). Since the Pro8 residue responsible for this bend is 
missing in P8A, only the interaction between the two P8A molecules through N- and C­
terminal regions becomes the major driving force for fibril formation (Figure 4.3 b ). The 
linear conformation in this mutant peptide lacking the turn conformation decreases the 
fibril formation rate (Figure 4.2). 
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Figure 4.3 Schematic Representation of the Aggregation of a) Len 1-22 Fibrils b) P8A 
Fibrils 
A recent solid state NMR study [55] has shown that AP1-40 has a bend structure 
conformation in its fibril structure, encompassing residues D23VGSNKG29 with a close 
contact between side chains of Asp23 and Lys28. Another group [56] demonstrated that 
formation of this bend structure is a rate limiting step in the AP1-40 fibril formation. In 
this study, a peptide with a lactam bridge between the side chains of Asp23 and Lys28 
(AP 140 (D23/K28)) was synthesized and used in the formation of fibrils. The structure of 
these fibrils was similar to the ones formed from AP 1-40. However the kinetics of 
fibrillogenesis occurred with a rate of -- 1000-fold greater than is seen with AP 1-40 
fibrillogenesis. This indicated that, since the bend structure conformation was already 
established in the (AP140 (D23/K28)), the rate limiting step was eliminated in formation 
of fibrils from AP 1-40. 
Our results demonstrated that, Len 1-22, P8A and P8S formed fibrils. However 
the kinetics of fibril formation by Len 1-22 was faster than P8A or P8S. Therefore the 
formation of a turn structure in Len 1-22, thought to be anchored by Pro8, appears to be 
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important in forming the conformation of Len 1-22 required to make fibrils. As P8A can 
also form fibrils, this tum is not absolutely critical for fibril formation. Nevertheless the 
bend structure in Len 1-22 appears to have favored a conformation resulting in a faster 
rate of fibril formation as compared to P8A, indicating the importance of Pro8 in fibril 
formation. In the case of P8A, this peptide might be trying to generate a tum structure, 
before it actually forms fibrils which would actually result in a longer lag time before 
forming fibrils, since it can never achieve the bend conformation due to the P8A 
substitution. For P8S, the conformation for forming fibrils is harder to interpret, since the 
residue Ser is also a tum forming amino acid [49]. However since the structure 
recognized by 11-1 F4 and the rate of fibril formation is altered by the P8S substitution, 
the conformation adopted by P8S for making fibrils would appear to be different. 
Therefore, it has been shown that the same regions that bind the 11-1 F 4 antibody 
with high affinity are also required for fibrillogenesis. In addition, mutations that hinder 
antibody binding also drastically decrease the rate of fibril formation. The 11-1 F 4 mAb 
binds an epitope that is involved in the fibril formation of light chain proteins. 
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Chapter 5. Characterization of Len 1-22 and P8A Fibrils by Thioflavin 
T, Electron Microscopy and l l-1F4 Binding Assays 
Abstract / Rationale 
In this Chapter, the conformational differences of the fibrils grown from Len 1-22, 
P8A and P8S peptides were compared by 11-1F4 binding affinity assays using a EuLISA. 
The structures of the fibrils were also examined by Electron Microscopy (EM) and 
structural differences compared. 
The 11-1F4 binding affinities for P8A and P8S fibrils were also determined and 
shown to be lower than for Len 1-22 fibrils. This indicated that l l-1F4 was recognizing 
an epitope in the Len 1-22 fibrils which was absent in the P8A and P8S fibrils. However, 
according to the EM results, only the P8A fibrils were structurally different from Len 1-
22, whereas P8S and Len 1-22 fibrils appeared similar. P8A fibrils were formed from 
shorter filaments which increased the diameter of the fibrils, whereas P8S and Len 1-22 
fibrils were formed from longer twisting filaments. Therefore the alteration in the 
conformation of fibrils due to P8S substitution was not reflected in the EM images. 
The conformation and the packing of Len 1-22, and P8A fibrils, the location, 
nature of the amino acid substituted in the fibrillogenic sequence and the effect on the 
arrangement of fibrils are discussed. 
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Results and Discussion 
In previous experiments (Chapter 4), the minimal region in the Len VL domain for 
fibril formation was shown to be Len 1-22, by in vitro fibril formation assays. In addition, 
it was shown that P8A and P8S were capable of forming fibrils, although at a slower rate. 
It was also shown that the 11-1F4 binding to the Len 1-22, P8A and P8S was decreased, 
indicating their conformational differences (Chapter 3). 
Since 1 l -1F4 is known to recognize a conformational epitope on the fibrils of the 
Len VL domain [29], in the experiments presented here, 1 l -1F4 binding affinity to fibrils 
formed from Len 1-22, P8A and P8S was measured by EuLISA and compared. EM was 
used to examine the fibril structures formed from these peptides. 
One of the goals of these experiments was to investigate whether the P8A or P8S 
substitution were also altering the conformational epitope on the fibrils formed from 
these peptides, affecting the 11-1 F 4 binding affinity. In addition, the structural 
differences of these fibrils were examined using EM images. Fibrils were grown from 
these peptides as explained in Materials and Methods. ThT was used to monitor fibril 
growth until complete (1 day for Len l -22 and 7-8 days for P8A) (Figure 5. 1).EM images 
showed that P8A fibrils were made out of shorter filaments compared to P8S and Len 1-
22 fibrils. The stacking of these shorter filaments increased the diameter of the fibrils 
grown from P8A (Figure 5.2). Although P8S was conformationally different from Len 1-
22, demonstrated by the 1 l -1F4 binding affinity assays (Chapter 3), the structure of the 
fibrils formed from both P8S and Len 1-22 were similar and made up of longer filaments. 
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Figure 5.1. ThT binding to Len 1-22, P8A and P8S fibrils after 7 days of shaking at 37°C 
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Figure 5.2. Electron Microscopy Images of Fibrils. a) Len 1-22 (Mean Fibril Width = 9.2 
nm ± 0.73) b) P8S (Mean Fibril Width = 9.3 nm ± 1.2) c) P8A Fibrils (Mean Fibril Width 
= 13 nm ± 1.9). Widths of 10 discrete fibrils were used to calculate the Mean Fibril 
Width. Measurements were made using the Image J Software Package 
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In agreement with the slower rate of fibril formation from P8A compared to Len 1 -22, the 
EM results suggested that the P8A might be forming a different intermediate on its 
pathway of fibril formation. According to the EM images, the increased length of fibrils 
of Len 1 -22 compared to P8A, suggested that the conformation of Len 1 -22 for extending 
into fibrils was more suitable than P8A. If the hypothesis about the linear conformation 
of P8A is valid, the stacking of the shorter filaments seen in the EM images could be 
explained due to this linear conformation, where the extension of the fibrils is not 
complete. The tum structure of the Len 1 -22 on the pathway of its fibril formation could 
be forming a stable partially folded conformation due to both intra and intermolecular 
interactions, resulting in a more efficient fibril extension. 
The binding affinity of 1 1 - 1F4 for Len 1 -22 fibrils was altered by both the P8A 
and P8S substitution. The EC50 value for both P8A and P8S fibrils were - 5 x 10-7 M 
where as the same value for Len 1 -22 fibrils was - 3.98 x 10- 10 M (Figure 5.3). This 
showed that l 1 -1F4 was recognizing the conformation on the Len 1 -22 fibrils with higher 
affinity. This result demonstrated the specificity of 11- 1F4 for a certain conformational 
epitope in the Len 1 -22 fibrils, which was absent in the P8A or P8S fibrils. Although EM 
images demonstrated similar fibril structures for P8S and Len 1 -22, the conformational 
differences between the fibrils were obvious from the differences in their 1 1 - 1F4 binding 
affinities. 
Two possibilities concerning 1 1 - 1  F 4 recognition of the denatured state of Len 1 -
22 were mentioned in Chapter 3. One possibility was the Pro8 residue generated a �-tum, 
bringing the N- and C-terminal residues closer in proximity, and this tum conformation 
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Figure 5.3. Comparison of l l -1F4 Binding to Len 1-22 ( £ ), P8A (+) and 
P8S C•) Fibrils 
was recognized by 11-1F4. The second possibility was the N- and C-terminal regions of 
two different Len 1-22 peptides interacted with each other in a linear conformation and 
l l -1F4 recognized these regions of the two peptides in close proximity (Figure 4.3 b). 
The EM images of Len 1-22 and P8A fibrils and l l -1F4 binding affinity assays for the 
fibrils provide evidence that the first possibility is more likely. The EM images show that 
the proposed linear conformation of the P8A resulted in stacking of shorter filaments, that 
was not recognized by 11-1F4, therefore the 11-1F4 could not be recognizing Len 1-22 in 
a linear epitope. 
The idea that monoclonal antibodies (mAbs) generated against fibrils are 
conformation specific rather than sequence specific was also previously demonstrated by 
other studies (42] (47]. One of these studies has shown that conformation-specific mAbs 
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WOl and W02, which were originally generated against the A� (1 -40) fibrils, were able 
to bind to fibrils formed from other peptides such as islet amyloid polypeptide (IAPP), 
transthyretin (TTR), �2-microglobulin (�2m) and JT05, suggesting a similar epitope 
within these fibrils. Although IAPP has a similar sequence to A� (1 -40), there was no 
sequence similarity of A� ( 1 -40) with the rest of the peptides. In addition WO 1 was 
capable of binding to polyGln aggregates which have amyloid like features [47] . The 
other study reported the generation of two mAbs against the amyloidogenic TTR 
mutants, where the three amino acids of the D strand had been removed (TTRdel53-55) 
or substituted (TTRs53-55) with other amino acids [42] . The two different mAbs (mAb 15  
and mAb4 7) were shown to recognize two different cryptic epitopes on these mutants and 
ex vivo TTR amyloid. These antibodies did not recognize the wild type TTR or other 
TTR variants such as V30M and L55P, unless in denaturing conditions. This suggested 
that the conformational change as a result of a mutation or a deletion in the 53-55 region 
exposed two different regions in the (TTRdel53-55), (TTRs53-55) and ex vivo TTR 
amyloid which were hidden in the wild type TTR, and the other TTR variants (V30M and 
L55P). The epitopes were located in regions distinct from 53-55 region, demonstrating 
that the region where the mutations were located was not a significant part of the epitope. 
This showed that the mutations or deletions in one part of the molecule can result in a 
conformational change in a different part of the molecule. In agreement with these 
studies, our results demonstrated that a single amino acid variation in the same sequence 
could result in a difference in the conformational epitopes exposed by the fibrils. The 
location of the mutation and the nature of the amino acid is important in altering the 
conformation of the pathway intermediates and the fibril structures. 
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In many studies, scanning mutagenesis has been used extensively to measure the 
effect of a single amino acid changes on the secondary structure of peptides/proteins and 
amyloid fibril formation [25] [57]. The most common amino acids used for substitution 
are alanines and prolines, depending on how they are considered to have an effect on the 
secondary structure. 
In the literature, proline scanning mutagenesis was used to examine the secondary 
structure of fibrils made from AP ( 1 -40) [25] [50] . In these experiments, two 
amyloidogenic peptide fragments ( 15-23) and ( 12-26) corresponding to the core of the 
AP ( 1 -40) fibrils were used. The aim of these experiments was to see whether proline 
replacement of an amino acid in these regions would disturb the extended P-sheet 
structure, which would eliminate fibril formation. These investigators revealed that, the 
residues in the region 17-23 were sensitive to proline replacement. The proline 
replacement of any of these residues resulted in an increase in peptide solubility and 
eliminated fibril formation [50] . Another study [51 ]  using NMR spectroscopy, has shown 
that F19T mutation in the sequence AP ( 10-35)-NH2 encompassing this region resulted in 
an alteration in this peptide's conformation. The F19T peptide was also shown to be 
incapable with AP plaque growth compared to the wild type AP (10-35)-NH2. These 
studies have shown that, in a region critical for fibril formation, replacement of a single 
amino acid by proline disturbed the extended P-sheet conformation sufficiently to prevent 
fibril formation and deposition. This effect on fibril formation was linked to a change in 
the peptide conformation due to a single amino acid substitution. Our results with Len 1 -
22 and its mutant peptides also showed that a single amino acid substitution in the 
sequence of 1 -22 altered the conformation of the peptide shown by the 1 1-1F4 binding 
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assays (Chapter 3). The fibril formation was not abolished due to this mutation, but the 
rate decreased (Chapter 4). In addition, as shown by the EM images (Figure 5.2), the 
structure of the P8A and Len 1 -22 fibrils were different, likely as a result of this 
conformational change. However, according to these results, the conformational 
difference of the P8S fibrils is not reflected in the EM images, as the fibrils of Len 1 -22 
and P8S appear similar in structure. Therefore a hypothesis about the conformation of the 
P8S fibrils is not possible at this point. 
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Chapter 6. Limited Proteolysis Experiments for Determining the 
Structural Differences between Len 1-22 and P8A Fibrils and 
Monomers 
Abstract /Rationale 
In previous chapters, the differences in the 11-1F4 binding to Len 1-22, P8S and 
P8A in both their soluble and fibrillar forms, their rate of fibril formation and the 
structural differences in their fibrils were demonstrated using various techniques. The 
results of these experiments suggested the structural conformation of Len 1-22 differed 
from that of P8S and P8A due to the single amino acid substitution. The P8A and PSS 
peptides were essentially identical in these analyses. Therefore, to examine the 
importance of this point mutation further, limited proteolysis experiments were 
performed using chymotrypsin followed by mass spectrometry to map differences in the 
fragmentation patterns of Len 1-22 and P8A (as an example of both mutants) both their 
soluble and fibrillar forms. The aim of these experiments was to document the structural 
difference between the Len 1-22 and P8A fibrils. 
Results and Discussion 
These studies are based on similar work involving the structural characterization 
of the AP fibrils [48]. In these experiments limited proteolysis experiments was 
conducted using AP ( 1-40) monomer and fibrils, and the data were compared in order to 
determine the regions protected in the core of the AP (1-40) fibrils, according to the 
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kinetics of fragmentation by various proteases. The method is based on determining the 
solvent exposed regions of the protein or peptide according to its protease accessibility 
manifest by the cleavage patterns observed by mass spectrometry. Although other 
techniques such as HID exchange - NMR, solid state NMR or x-ray crystallography are 
being used to obtain information about structures with amino acid resolution [58] [59] 
[60], limited proteolysis is informative when comparing poorly structured and/or flexible 
regions vs the protease resistant structured regions of the protein [48] [61]. For these 
studies, enzymes with different cleavage sites may be used depending on the sequence of 
the protein. As Len 1 -22 is a short sequence, chymotrypsin was used in order to get a 
diverse fragmentation pattern. Chymotrypsin is capable of cleaving sequences at the C­
terminal of residues Phe, Tyr, Trp, Leu, Met, Ile, Thr, and Val. In addition, some 
cleavage is also observed at the C-terminal sites of Ser and His residues. The theoretical 
fragmentation of both Len 1 -22 and P8A using this enzyme is shown in Figure 6. 1 .  
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Figure 6.1 .  Theoretically Possible Enzymatic Cleavage Sites of Len 1 -22 (A) and P8A 
(B) Using Chymotrypsin 
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Len 1-22 and P8A Monomer 
Len 1-22 and P8A monomer were solubulized and subjected to limited proteolysis 
according to the protocol in the Materials and Methods. ESI-MS was used to analyze the 
fragmentation pattern, following the chymotryptic digestion. An aliquot of each of the 
peptide solutions, before digestion, was analyzed by ESI-MS, for the purpose of a 
control. Following a 5 min digestion, -50% of Len 1-22 monomer and 90% of P8A were 
digested; therefore aliquots at later time points were not analyzed. The differences in the 
fragmentation pattern of the soluble Len 1-22 and P8A are shown in Figure 6.2. 
Following digestion, different fragmentation patterns were obtained from P8A compared 
to Len 1-22 (Table 6.1). The cleavage around Leu l l and at N-terminal of the Ala8 in 
P8A monomer, 1-11, 12-21 and 8-21 fragments, suggested that this peptide was flexible 
in this region and therefore prone to proteolysis. In addition, fragment 8-21 was seen as 
the main peak after only 5 min digestion, compared to the P8A peptide in the control 
sample. None of these cleavages were observed in Len 1-22. The fragment 1-15, and the 
intact 1-22 eluted at the same time within the main peak, whereas 5-15 and 1-13 eluted at 
an earlier time with a lower peak intensity (Figure 6.2 a, Table 6.1 ). This indicated that 
smaller fragments formed as a result of Len 1-22 digestion, were also smaller in quantity, 
and Len 1-22 remained intact (for the most part), or with a 7 residue truncation at the C­
terminal region after 5 min. In addition, these data imply that the region around Pro8 
within Len 1-22 was more structured with lesser solvent accessibility compared to same 
position in P8A. Although the peaks for the fragments 11-21 and 14-22 were present in 
the Len 1-22 control sample, there was no digestion of these fragments; moreover 11-22 
appeared as a very minor component when compared to intact 1-22. 
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Table 6.1 Fragments Obtained from Proteolytic Digestion of Len 1-22 (upper chart) and 
P8A (lower chart) Monomers 
Fragments / Fragments Retention time 
Digestion time (min) 
I Control 1 1 -2 1 77.76 
(no digestion) 1 -2 1  94.45 
1 -21 95 .73 
14-22 99.09 
1 -22 ( oxidized) 101 .26 
1 -22 107.68 
5 min 1 -1 3  66. 16 
5-15 66. 16 
14-22 72.35 
I 1 - 1 5  79.86 
1 -22 79.96 
, Control 16-22 9 1 . 1 0 
(no digestion) 15-22 9 1 . 10 
14-22 9 1 . 10 
1 -22 1 1 5.62 
I 
5 min 1 - 1 1 100.47 
5- 15 103 .72 
12-2 1 109.79 
16-22 109.79 
1 -22 1 1 5.92 
8-21 143.7 
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I 
Calculated mass 
(Da) 
1 129.322 
2203 .500 
2203 .500 
960.055 
2333.59 
23 17.603 
1375.563 
1 1 17.222 
960.055 
1575.801 
23 17.603 
1 759.8 1 8  
j 872.977 
960.055 
2291 .566 
1 1 79.3 14 
109 1 . 1 84 
10 16. 163 
759.8 18  
2291 .566 
1402.568 
Measured mass 
(Da) 
I 1 128.80 
2203 .60 
2203 .60 
959.80 
2332.6 
23 17. 10 
1375 .040 
1 1 16.80 I I 
959.80 
1 575.26 
I 23 1 7. 10 
759.540 
872.800 
959.800 
2291 .600 
i I 
1 178.55 
1090.8 
10 1 5 .80 
759.79 
2291 . 1 1 
1403 .98 
Therefore these fragments did not hamper our interpretation of the results after digestion. 
As for the P8A control sample, other than 1 -22, small fragments from the C-terminal 
region including 14-22, 15-22, 16-22 were also present as minor components in the main 
peak. Similarly, there appeared to be no digestion of these fragments to complicate our 
analyses. The only fragment common to both P8A and Len 1 -22 was 5-1 5, which had 
similar peak intensities; therefore, the flexible structure proposed for P8A may be in 
equilibrium with the more compact form adopted by Len 1 -22. Furthermore, absence of 
1 - 1 1 ,  12-22 or 8-2 1 after the digestion of Len 1 -22 suggests that the region encompassing 
5-1 3  is highly protected in the Len 1 -22 monomer in solution. 
Len 1-22 and P8A Fibrils 
In order to compare the structural differences between Len 1 -22 and P8A as 
fibrils, similar proteolysis experiments were performed. The only difference between 
these experiments was that, aliquots after 1 25 min digestion were analyzed in addition to 
the 5 min digestion, because the fibrillar forms of these peptides were far more resistant 
and required longer periods of incubation with the enzyme compared to the soluble 
forms. In addition, the variation in the digestion patterns of Len 1 -22 and P8A fibrils after 
125 min chymotrypsin incubation provided information on their relative stability and 
structure. The fragments of the fibrils obtained after 5 min and 125 min chymotryptic 
digestion were compared. The aim of these experiments was to examine the differences 
in protease - resistant regions in each fibril and to predict the region constituting the core 
of the fibril itself. These results will aid in predicting which parts of Len 1 -22 and P8A 
peptide self associate during fibrillogenesis . 
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The stability of the fibrils was determined by comparing the peak profiles ( on the 
HPLC) after proteolytic digestion for 5 min and 125 min. Although these results do not 
provide an exact quantification of the fragments, the increase in the intensity of the peaks 
relative to the main peak for Len 1-22 and P8A fibrils after 5min and 125 min digestion 
provide a relative quantification. During the ESI-MS analysis of Len 1-22 fibril aliquots, 
the intensity of the peaks could not be measured because there was a second peak 
containing intact Len 1-22 eluting at a later time. This elution profile was unique to Len 
1-22 fibrils and hampered the analyses of relative peak intensities. After proteolytic 
digestion, both Len 1-22 and P8A fibrils required solubulization before they were infused 
to ESI-MS through a capillary column, as the insoluble fibrils clogged the column. 
Therefore 5 min and 125 min digestion aliquots from both fibrils were solubulized using 
the TF A/HFIP protocol. 
After a 5 min digestion, Len 1-22 fibrils remained mostly intact (Figure 6.3 a). 
The fragments obtained at this time point, were similar to the fragments of Len 1-22 in its 
soluble form with the exception of 5-13 and 6-15. However the intensity of the peaks for 
the fragments 5-15 and 1-13 were higher after the digestion of the fibrils, which indicated 
that the region between 5 and 13 were protected after fibril formation as compared to 
soluble form. The presence of 5-13 and 6-15 also indicated the middle region in the 
sequence was forming a structure highly resistant to proteolytic digestion when 
incorporated in the fibril. Although 6-15 has the similar molecular weight as the 
fragments 12-21 and 11-20, the peak corresponding to this fragment is most likely to be 
6-15, since 1-11 or 1-10 are absent in the mass spectrum (Figure 6.3 a). 
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In addition, 12-21 or 11-20 were not present even after the 5 min digestion of the soluble 
Len 1-22 (Figure 6.2 a). At the end of 125 min of digestion, fragments such as 5-13, 5-15, 
and 6-15 were observed in the Len 1-22 fibril sample (Figure 6.3 a). Even after 125 min 
of Len 1-22 fibril digestion, there was no indication of cleavage around the Pro8 and 
Leu 11 residues. The reason for lack of cleavage in this region may be a result of a tum 
structure due to Pro8 bringing the residues 5-13 in closer proximity, providing the 
interaction of these residues during fibril formation. Although 5-15 and 1-13 appears also 
to be protected in the soluble Len 1-22, the resistance to proteolytic digestion is more 
pronounced when incorporated in the fibril structure, shown by the increased intensity of 
the peaks corresponding to these fragments. These results suggest that the region 
encompassing 5-13 may be the protease resistant core of Len 1-22 fibrils. 
For the P8A fibrils, the 5 min digestion (Figure 6.3 b) {Table 6.2) resulted in 
fragments of similar length compared to 5 min digestion of Len 1-22 fibrils (Figure 6.3 a) 
although with slightly different cleavage sites. In spite of the fibril structure, the 
cleavages at the C-terminal of Leu l l and the N-terminal of Ala8 were still present and 
the intensity of the fragment 8-21 was comparable to the intensity of the same fragment 
obtained after 5 min digestion of the soluble form of P8A. However the undigested P8A 
fibrils still remained as the main peak after 5 min digestion. In contrast, incubation of 
chymotrypsin with P8A fibrils for 125 min resulted in numerous small fragments (Figure 
6.3 b ). The digestion of P8A fibrils after a prolonged period not only resulted in various 
truncations at the N and C-terminal regions of the P8A fibrils (5-14, 3-13, 4-13, 3-20, 3-
21, 8-15,6-13, 5-15, 15-22) but also in cleavage within these fragments at critical points 
(N-terminal of Pro8 and C-terminal of Leul 1). 
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Table 6.2 Fragments Obtained from Proteolytic Digestion of Len 1-22 (upper chart) and 
P8A (lower chart) Fibrils 
Fragments/ Fragments Retention time Calculated mass Measured mass (Da) 
Digestion time (min) (Da) 
Control 1 -2 1  1 05.94 2203 .500 2203 . 100 
(no digestion) 1 -22 ( oxidized) 1 08.7 1 2332.26 2333.590 
1 -22 1 1 3.87 23 17.603 23 16.600 
5 min 5- 1 3  75.60 9 1 6.984 9 16.80 1 
5- 15  82.87 1 1 1 7.222 1 1 6.80 
1 - 13 82.87 1375.563 1 375.03 
6-15  89. 1 8  10 16. 1 63 1 0 1 5 .8 
1 - 1 5  98.25 1 575.801 1 575.58 
1 -22 · 1 04.20 23 1 7.603 23 17.363 
1 25 min 5- 13  6 1 .23 9 16.984 9 16.80 
5- 15  74.5 1  1 1 17.222 1 1 1 6.80 
6-1 5  76.44 1 016. 1 63 1 0 1 5.80 
1 5-22 88.28 872.977 873.80 
1 -22 95.43 23 1 7.603 23 1 8. 1 0  
Control 1 -22 1 14.05 229 1 .566 2292. 1 0  
(no digestion) 
5 min I 3-1 3  76.92 1 12 1 .277 1 1 2 1 .800 
1 -1 1  78.96 1 179.3 14 1 1 78.800 
1 -22 83 .47 2291 .566 2292. 1 00 
8-2 1  1 37.73 1402.568 1402.280 
1 25 min 12-22 49.46 1 1 30.267 1 1 29.800 
5-14 53.96 978.024 977.800 
3-1 3  53.96 1 12 1 .277 1 1 2 1 .800 
I 5-1 1  56.85 720.735 7 19.540 
3-20 56.85 1 836.054 1 835. 1 00 
1 - 1 1 56.85 1 179.3 14 1 1 78.800 
12-20 57.99 903.004 902.800 
I 4- 1 3  58.05 1022. 145 1 022.800 
8-1 5  62.38 774.870 774.540 
6-1 3  62.38 789.841 790.790 
5-1 5  6
°
2.38 1 09 1 . 1 84 1 090.800 
12-2 1  70.55 1016. 1 63 1 01 5.800 
4-22 8 1 .24 1 964. 1 85 1963.600 
1 -22 83.89 229 1 .566 229 1 .600 
1 5-22 87.55 872.977 873.800 
I 3-2 1  87.55 1 949.2 14 1 948. 1 00 
- -
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These results implied that the P8A fibrils had a less compact structure in the region 
encompassing 5-13, whereas this region appeared to be more organized in the Len 1-22 
fibrils and more resistant to digestion. 
At this point, it is difficult to predict the core of the P8A fibrils, due to the 
multiple cleavage sites throughout the peptide. Even for the Len 1-22 fibrils, where some 
cleavage sites present in P8A fibrils (1-11, 8-21) are protected from cleavage, the data 
presented here do not precisely define the core of the Len 1-22 fibril, but only imply that 
residues within 5-13 may be incorporated and thereby protected. But, these results do 
nevertheless clearly demonstrate conformational differences between Len 1-22 and P8A 
fibrils and monomers manifest by the different fragmentation patterns which may explain 
why the Len 1-22 and P8A fibrils appeared different in EM images and the difference in 
the 11-1F4 binding affinities for Len 1-22 and P8A fibrils. 
Further studies such as HID exchange-MS will be required to compare differences 
in the core regions of fibrils of the Len 1-22 and P8A fibrils. This technique is based on 
determining the amide hydrogen exchange of each residue with deuterium based on their 
solvent accessibility [58]. Such an approach can provide data about which residues are 
involved in the H-bonded network of fibrils. HID exchange is usually coupled with NMR 
although recently mass spectrometry was used as a tool for data analysis [62]. Therefore 
WD exchange experiments for determining the structure of Len 1-22 and P8A fibrils 
would provide better atomic resolution and therefore increased understanding about the 
location of each residue and their relative incorporation in the fibril structure. 
Other techniques for determining the conformation of fibrils include Cys-, Ala-, 
and Pro- scanning mutagenesis [25] [63] [64]. This method is based on substituting each, 
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or certain residues within a sequence, with either Cys, Ala, or Pro, in order to determine 
the effect of these substitutions on secondary structure of the protein [57] [63] [64]. All 
three types of amino acid scanning mutagenesis coupled with HID experiments have been 
performed on A� (1-40) fibrils to determine the sensitivity of each residue to the 
substitution of these amino acids for fibril formation and how the stability of the fibrils 
formed from these mutant peptides are altered with respect to the wild type A� ( 1-40) 
fibrils [25] [63] [64]. 
Alanine scanning mutagenesis experiments using Len 1-22 have been performed 
(data not shown) to determine the importance of each residue on the conformation of Len 
1-22 recognized by 11-1F4. Since 11-1F4 recognition coincides with the fibrillogenic 
region of the Len V L derived peptides, understanding the function of each residue for 11-
1 F 4 recognition could provide insights into how each mutation will affect fibril stability 
or fibril formation. Further analysis by alanine scanning mutagenesis could also provide 
insight about the possible conformation of the amyloidogenic intermediate state of V L 
that forms on the pathway to fibril formation. However, it must be taken into 
consideration that 1-22 could be only one of the minimal (initiation) sequences that foster 
fibril formation within the context of the whole Len V L· In addition, other residues such 
as Tyr 96 in Len (Pro96 in Rec and Gin in Sma) which may or may not be in the minimal 
region / regions could decrease the amyloidogenic potential of Len V L domain, by 
increasing the overall stability of Len. Such a situation was observed in a study where Pro 
was substituted for a central hydrophobic amino acid in each strand of �2m [57]. Three of 
these mutations had a dramatic affect on fibril formation, but only one of these mutations 
was located in the K3 region defined to be the minimal region for �2m fibrillogenesis. 
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This again showed that residues in other locations may also contribute via long range or 
domain-wide perturbations to its amyloidogenic behavior. 
The different fragmentation patterns obtained from both Len peptides suggested 
that the region encompassing the 8th residue was more structured in Len 1-22 compared 
to P8A in both soluble and fibrillar form of these peptides. Although, it is difficult to 
propose a specific secondary structure for the peptides in the soluble form, the results 
presented here indicate that the nature of the 8th residue is important in determining how 
the sequence is fragmented even before the peptides are incorporated in the fibril 
structure. The studies presented in this Chapter represent only the beginning of 
understanding the structure of fibrillogenic region/regions and the amyloidogenic 
potential of the immunoglobulin light chain proteins. Understanding the conformation of 
1-22, is important for future drug designs that recognize this region and which may 
inhibit fibril formation of light chains. 
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Chapter 7. Conclusion 
In this study, the fibrillogenic region of the Len VL domain was partially mapped 
by in vitro fibril formation assays using peptides corresponding to different regions of the 
VL N-terminal domain. The results showed that the fibrillogenic region was confined to 
the first 22 residues of the N-terminal. Even though Len was non-pathological with no 
signs of forming amyloid fibrils in vivo, mild destabilization of the Len V L domain in 
vitro resulted in fibril formation [ 14]. This suggested that if the Len V L was destabilized 
enough to expose certain fibrillogenic regions, it was certainly capable of forming fibrils. 
The fibrillogenic behavior of �2m under physiological conditions was explained by a 
study using similar experimental approaches [ 16]. Although seed-dependent extension of 
the intact �2m was optimum at pH 2.5 [19], a 22-residue peptide (Ser2°-Lys4 1) named K3, 
obtained by digestion of �2m, was shown to be capable of forming fibrils around 
physiological pH (-7 .5). This study demonstrated, that if the whole �2m molecule was 
destabilized and unfolded to expose regions such as Ser2° -Lys4 1 , �2m had a strong 
potential to form fibrils under physiological conditions. Ser2°-Lys41  is considered to be 
one of the essential or minimal sequences within �2m required for its fibril formation 
[16]. In many other amyloidogenic proteins, similar regions were also shown to contain 
initiation sites for amyloid fibril formation of the whole molecule [65]. The formation of 
fibrils from the intact Len V L domain required the destabilization of its structure [ 14]. 
However, the experiments presented here demonstrated that Len 1-22, similar to the 
action of K3, was shown to be fibrillogenic without any seeding or mild destabilization. 
11- 1F4, which only recognized the fibrils of the Len VL and not the soluble form, was 
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shown to have the highest binding affinity for the Len 1 -22 peptide. These results implied 
that this region might also be the minimal region or the initiation site for fibril formation 
from Len Vt. 1-22 is also conserved in the sequence of two homologs of Len, Sma and 
Rec, which show pathological behavior in vivo. Given that Sma and Rec have a lower 
stability than Len, 1 -22 might be more prone to be exposed in the pathological light 
chains and initiate fibril formation in vivo. This might be one of the explanations for the 
pathological behavior of Sma and Rec, but this assumption would require further 
structure/ function studies such as HID exchange. 
Given that 1 1 -1 F 4 was shown to recognize a common epitope structure within 
different amyloid fibrils and does not interact with the soluble form of the proteins, this 
epitope is suggested to be conformational rather than linear. Understanding the 
conformation of the epitope recognized by l 1 - 1F4 is important for understanding the 
mechanism of aggregation of LCs which might be useful for diagnostic and therapeutic 
purposes including drug design. 
In order to provide insight into the conformation of Len 1-22 fibrils recognized by 
l l- 1F4, a single site substituted form of this peptide (P8A) was used to form fibrils and 
the binding characteristics of l l - 1F4 were compared to those with Len 1 -22 fibrils. 
According to our hypothesis, Pro8 is thought to be in a critical position in the Len 1 -22 
sequence that is thought to anchor a P-turn region. According to our results, the 
substitution of Pro8 with Ala, an amino acid not well accommodated in a P-tum 
conformation, was shown to affect the conformation of the fibrils formed from P8A and 
also inhibit binding of the l l - 1F4. The l l - 1F4 affinity for P8A fibrils was drastically 
lower compared to Len 1 -22 fibrils shown by the ECso values. Differences in the 
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conformation of the mutant peptide and the native peptide both in the soluble form and 
fibrillar form were also observed using limited proteolysis experiments manifest by the 
different fragmentation patterns. 
These results suggest the importance of the location of the Pro8 and the nature of 
the residue at this position in forming the specific conformation required for V L 
fibrillogenesis. Although the fibrillogenic region (1 -22) might be incorporated differently 
in the context of the whole Len V L domain during fibril formation, the results imply that 
there is a unique conformation of the fibrillogenic region recognized by 1 1 -1F4, which is 
not present in the native soluble structure. 
70 
References 
7 1  
References 
1. Obici, L., et al., Clinical aspects of systemic amyloid diseases. Biochim Biophys 
Acta, 2005. 1753( 1): p. 11-22. 
2. De Lorenzi, E., et al., Pharmaceutical strategies against amyloidosis: old and 
new drugs in targeting a ''protein misfolding disease ". Curr Med Chem, 2004. 
11(8) : p. 1065-84. 
3. Dobson, C.M., Principles of protein folding, misfolding and aggregation. Semin 
Cell Dev Biol, 2004. 15(1 ): p. 3-16. 
4. Nilsson, M.R., Techniques to study amyloid fibril formation in vitro. Methods, 
2004. 34(1) : p. 151-60. 
5. Perfetti, V., G. Palladini, and G. Merlini, Immune mechanisms of AL amyloidosis. 
Drug Discovery Today: Disease Mechanisms, 2004. 1(3): p. 365-373. 
6. Bourne, P.C., et al., Three-dimensional structure of an immunoglobulin light­
chain dimer with amyloidogenic properties. Acta Crystallogr D Biol Crystallogr, 
2002. 58(Pt 5): p. 8 15-23. 
7. Harlow, E. and D. Lane, Antibodies (A Laboratory Manual). 1988, New York: 
Cold Spring Harbor Laboratory. 
8. Falk, R.H., R.L. Comenzo, and M. Skinner, The systemic amyloidoses. N Engl J 
Med, 1997. 337(13): p. 898-909. 
9. Pokkuluri, P.R., et al., Tertiary structure of human lambda 6 light chains. 
Amyloid, 1999. 6(3): p. 165-71. 
72 
10. Huang, D.B., et al., Variable domain structure of kappa/V human light chain Len: 
high homology to the murine light chain McPC603. Mol Immunol, 1997. 34( 1 8) :  
p. 129 1 -301 .  
1 1 . Merlini, G. and V. Bellotti, Molecular mechanisms of amyloidosis. N Engl J Med, 
2003 . 349(6): p. 583-96. 
12. Hurle, M.R., et al., A role/or destabilizing amino acid replacements in light-chain 
amyloidosis. Proc Natl Acad Sci U S  A, 1994. 91( 12): p. 5446-50. 
13 .  Stevens, P.W., et al., Recombinant immunoglobulin variable domains generated 
from synthetic genes provide a system for in vitro characterization of light-chain 
amyloid proteins. Protein Sci, 1 995. 4(3): p. 42 1 -32. 
14. Raffen, R., et al., Physicochemical consequences of amino acid variations that 
contribute to fibril formation by immunoglobulin light chains. Protein Sci, 1999. 
8(3): p. 509- 1 7. 
15 .  Kim, Y. ,  et al., Thermodynamic modulation of light chain amyloid fibril 
formation. J Biol Chem, 2000. 275(3): p. 1 570-4. 
16. Ohhashi, Y., et al. ,  Optimum amyloid fibril formation of a peptide fragment 
suggests the amyloidogenic preference of beta2-microglobulin under 
physiological conditions. J Biol Chem, 2004. 279( 1 1) :  p. 108 14-2 1 .  
17 .  Kelly, J.W., Alternative conformations of amyloidogenic proteins govern their 
behavior. Curr Opin Struct Biol, 1996. 6( 1 ): p. 1 1 -7. 
1 8. Nowak, M., Jmmunoglobulin kappa light chain and its amyloidogenic mutants: a 
molecular dynamics study. Proteins, 2004. 55( 1) :  p. 1 1 -2 1 .  
73 
19. Naiki, H., et al., Establishment of a kinetic model of dialysis-related amyloidfibril 
extension in vitro. Amyloid, 1997. 4: p. 223-232. 
20. Serag, A.A., et al., Arrangement of subunits and ordering of beta-strands in an 
amyloid sheet. Nat Struct Biol, 2002. 9(10): p. 734-9. 
21. Khurana, R., et al., A model for amyloid fibril formation in immunoglobulin light 
chains based on comparison of amyloidogenic and benign proteins and specific 
antibody binding. Amyloid, 2003. 10(2): p. 97-109. 
22. Bellotti, V., P. Mangione, and G. Merlini, Review: immunoglobulin light chain 
amyloidosis--the archetype of structural and pathogenic variability. J Struct Biol, 
2000. 130(2-3): p. 280-9. 
23. Abraham, R.S., et al., Immunoglobulin light chain variable (V) region genes 
influence clinical presentation and outcome in light chain-associated amyloidosis 
(AL). Blood, 2003. 101(10): p. 3801-8. 
24. Leung, N., et al., Long-term outcome of renal transplantation in light-chain 
deposition disease. Am J Kidney Dis, 2004. 43(1): p. 147-53. 
25 .  Williams, A.D., et  al . ,  Mapping abeta amyloid fibril secondary structure using 
scanning proline mutagenesis. J Mol Biol, 2004. 335(3): p. 833-42. 
26. Souillac, P.O., et al., Elucidation of the molecular mechanism during the early 
events in immunoglobulin light chain amyloid fibrillation. Evidence for an off­
pathway oligomer at acidic pH. J Biol Chem, 2002. 277(15): p. 12666-79. 
27. Souillac, P.O., et al., Effect of association state and conformational stability on 
the kinetics of immunoglobulin · light chain amyloid fibril formation at 
physiological pH. J Biol Chem, 2002. 277(15): p. 12657-65. 
74 
28. Souillac, P.O., V.N. Uversky, and A.L. Fink, Structural transformations of 
oligomeric intermediates in the fibrillation of the immunoglobulin light chain 
LEN Biochemistry, 2003. 42(26): p. 8094-104. 
29. Hmcic, R., et al. , Antibody-mediated resolution of light chain-associated amyloid 
deposits. Am J Pathol, 2000. 157(4): p. 1239-46. 
30. Stoppini, M., et al. , Use of anti-(beta2 microglobulin) mAb to study formation of 
amyloid fibrils. Eur J Biochem, 1997. 249( 1 ): p. 21-6. 
31. Alexandrescu, A.T., Amyloid accomplices and enforcers. Protein Sci, 2005 . 14( 1 ) : 
p. 1-12. 
32. Yamaguchi, I., et al., Apolipoprotein E inhibits the depolymerization of beta 2-
microglobulin-related amyloid fibrils at a neutral pH Biochemistry, 2001. 
40(29): p. 8499-507. 
33. Pepys, M.B., Amyloidosis. Annu Rev Med, 2006. 57: p. 223-41. 
34. Ohno, S., et al., The antisense approach in amyloid light chain amyloidosis: 
identification of monoclonal Jg and inhibition of its production by antisense 
oligonucleotides in in vitro and in vivo models. J lmmunol, 2002. 169(7): p. 4039-
45. 
35. Potera, C., Vaccines Offer Hope of Treating Neurodegenerative Disorder. Genetic 
Engineering News, 2002. 22(2). 
36. Hock, C., et al. , Generation of antibodies specific for beta-amyloid by vaccination 
of patients with Alzheimer disease. Nat Med, 2002. 8(11): p. 1270-5 . 
37. Lee, M., et al., Abeta42 immunization in Alzheimer's disease generates Abeta N­
terminal antibodies. Ann Neurol, 2005. 58(3): p. 430-5 . 
75 
38. Paramithiotis, E., et al., A prion protein epitope selective for the pathologically 
misfolded conformation. Nat Med, 2003. 9(7): p. 893-9. 
39. Korth, C., et al., Prion (PrPSc)-specific epitope defined by a monoclonal 
antibody. Nature, 1997. 390(6655): p. 74-7. 
40. Hanan, E., S.A. Priola, and B. Solomon, Antiaggregating antibody raised against 
human PrP 106-126 recognizes pathological and normal isoforms of the whole 
prion protein. Cell Mol Neurobiol, 2001. 21(6) : p. 693-703. 
41. Peretz, D., et al., A conformational transition at the N terminus of the prion 
protein features in formation of the scrapie isoform. J Mol Biol, 1997. 273(3): p. 
614-22. 
42. Goldsteins, G., et al., Exposure of cryptic epitopes on transthyretin only in 
amyloid and in amyloidogenic mutants. Proc Natl Acad Sci U S  A, 1999. 96(6) : p. 
3108-13. 
43. Sunde, M., et al., Common core structure of amyloid fibrils by synchrotron X-ray 
diffraction. J Mol Biol, 1997. 273(3): p. 729-39. 
44. Uversky, V.N. and A.L. Fink, Conformational constraints for amyloid 
fibrillation: the importance of being unfolded. Biochim Biophys Acta, 2004. 
1698(2) : p. 131-53. 
45. Glabe, C.G., Conformation-dependent antibodies target diseases of protein 
misfolding. Trends Biochem Sci, 2004. 29(10): p. 542-7. 
46. Dumoulin, M. and C.M. Dobson, Probing the origins, diagnosis and treatment of 
amyloid diseases using antibodies. Biochimie, 2004. 86(9-10): p. 589-600. 
76 
47. O'Nuallain, B. and R. Wetzel, Conformational Abs recognizing a generic amyloid 
fibril epitope. Proc Natl Acad Sci U S  A, 2002. 99(3): p. 1485-90. 
48. Kheterpal, I., et al., Structural features of the Abeta amyloid fibril elucidated by 
limited proteolysis. Biochemistry, 2001. 40(39): p. 11757-67. 
49. Lehninger, A.L., D.L. Nelson, and M.M. Cox, Principles of Biochemistry, 2nd ed. 
1982. 
50. Wood, SJ., et al., Prolines and amyloidogenicity in fragments of the Alzheimer's 
peptide beta/A4. Biochemistry, 1995 . 34(3): p. 724-30. 
51. Esler, W.P., et al., Point substitution in the central hydrophobic cluster of a 
human beta-amyloid congener disrupts peptide folding and abolishes plaque 
competence. Biochemistry, 1996. 35(44): p. 13914-21. 
52. Solomon, A., et al., Light chain-associated amyloid deposits comprised of a novel 
kappa constant domain. Proc Natl Acad Sci U S  A, 1998. 95(16): p. 9547-51. 
53. Makin, O.S., et al., Molecular basis for amyloid fibril formation and stability. 
Proc Natl Acad Sci U S A, 2005. 102(2): p. 315-20. 
54. Gazit, E., A possible role for pi-stacking in the self-assembly of amyloid fibrils. 
Faseb J, 2002. 16( 1 ): p. 77-83. 
55. Petkova, A.T., et al., A structural model for Alzheimer's beta -amyloid fibrils 
based on experimental constraints from solid state NMR.. Proc Natl Acad Sci U S 
A, 2002. 99(26): p. 16742-7. 
56. Sciarretta, K.L., et al., Abeta40-Lactam(D23/K28) models a conformation highly 
favorable for nucleation of amyloid. Biochemistry, 2005. 44( 16): p. 6003-14. 
77 
57. Chiba, T., et al., Amyloid fibril formation in the context of full-length protein: 
effects of proline mutations on the amyloid fibril formation of beta2-
microg/obulin. J Biol Chem, 2003. 278(47): p. 47016-24. 
58. Hoshino, M., et al., Mapping the core of the beta(2)-microg/obulin amyloid fibril 
by HID exchange. Nat Struct Biol, 2002. 9(5): p. 332-6. 
59. Platt, G.W., et al., Dynamics in the unfolded state of beta2-microglobulin studied 
by NMR. J Mol Biol, 2005. 346(1) :  p. 279-94. 
60. Trinh, C.H., et al., Crystal structure of monomeric human beta-2-microglobulin 
reveals clues to its amyloidogenic properties. Proc Natl Acad Sci U S A, 2002. 
99(15): p. 9771-6. 
61. Monti, M., et al., Topological investigation of amyloid fibrils obtained from 
beta2-microglobulin. Protein Sci, 2002. 11(10): p. 2362-9. 
62. Konermann, L. and D.A. Simmons, Protein-folding kinetics and mechanisms 
studied by pulse-labeling and mass spectrometry. Mass Spectrom Rev, 2003. 
22(1): p. 1-26. 
63 . Shivaprasad, S. and R. Wetzel, Scanning cysteine mutagenesis analysis of Abeta­
(1-40) amyloidfibrils. J Biol Chem, 2006. 281(2): p. 993-1000. 
64. Williams, A.O., S. Shivaprasad, and R. Wetzel, Alanine scanning mutagenesis of 
Abeta(l-40) amyloidfibril stability. J Mol Biol, 2006. 357(4): p. 1283-94. 
65. Krebs, M.R., et al., Formation and seeding of amyloidfibrils from wild-type hen 
lysozyme and a peptide fragment from the beta-domain. J Mol Biol, 2000. 300(3): 
p. 541-9. 
78 
Vita 
Demet Ataman was born in Ankara, Turkey on November 29, 1976. She 
graduated from TED Ankara Private High School in 1993 and then entered Middle East 
Technical University the following year. She received her Bachelor of Science with a 
major in Biology in 1999 and Master of Science with a major in Biochemistry in 2001 
from this university. She was accepted by the Genome Science and Technology for a 
graduate study in 2002 and received a Master of Science Degree from Comparative and 
Experimental Medicine in 2006. 
79 
e768 6501�2 I 
1 1  111Amr:: m 
